Calcium, Bioenergetics, and Parkinson’s Disease
Abstract
:1. Introduction: The Duality of Intracellular Ca2+ Signaling
2. Neuronal Ca2+ Homeostasis
3. Ca2+ and Control of Mitochondria
4. SN DAergic Neurons and PD
5. Ca2+ Signaling in SN DAergic Neurons
6. Why are SN DAergic Neurons Preferentially Vulnerable in PD?
7. Is Mitochondrial Dysfunction Sufficient to Cause PD?
8. Other Vulnerable Neuronal Populations
9. Conclusions and Future Directions
Funding
Conflicts of Interest
References
- Clapham, D.E. Calcium signaling. Cell 2007, 131, 1047–1058. [Google Scholar] [CrossRef] [Green Version]
- Raffaello, A.; Mammucari, C.; Gherardi, G.; Rizzuto, R. Calcium at the Center of Cell Signaling: Interplay between Endoplasmic Reticulum, Mitochondria, and Lysosomes. Trends Biochem. Sci. 2016, 41, 1035–1049. [Google Scholar] [CrossRef] [Green Version]
- Rizzuto, R.; Pozzan, T. Microdomains of intracellular Ca2+: Molecular determinants and functional consequences. Physiol. Rev. 2006, 86, 369–408. [Google Scholar] [CrossRef] [PubMed]
- Berridge, M.J.; Bootman, M.D.; Roderick, H.L. Calcium signalling: Dynamics, homeostasis and remodelling. Nat. Rev. Mol. Cell Biol. 2003, 4, 517–529. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Giorgi, C.; Danese, A.; Missiroli, S.; Patergnani, S.; Pinton, P. Calcium Dynamics as a Machine for Decoding Signals. Trends Cell Biol. 2018, 28, 258–273. [Google Scholar] [CrossRef] [PubMed]
- Poewe, W.; Seppi, K.; Tanner, C.M.; Halliday, G.M.; Brundin, P.; Volkmann, J.; Schrag, A.E.; Lang, A.E. Parkinson disease. Nat. Rev. Dis. Primers 2017, 3, 17013. [Google Scholar] [CrossRef]
- Obeso, J.A.; Stamelou, M.; Goetz, C.G.; Poewe, W.; Lang, A.E.; Weintraub, D.; Burn, D.; Halliday, G.M.; Bezard, E.; Przedborski, S.; et al. Past, present, and future of Parkinson’s disease: A special essay on the 200th Anniversary of the Shaking Palsy. Mov. Disord. Off. J. Mov. Disord. Soc. 2017, 32, 1264–1310. [Google Scholar] [CrossRef]
- Sulzer, D.; Surmeier, D.J. Neuronal vulnerability, pathogenesis, and Parkinson’s disease. Mov. Disord. Off. J. Mov. Disord. Soc. 2013, 28, 41–50. [Google Scholar] [CrossRef] [Green Version]
- Michel, P.P.; Hirsch, E.C.; Hunot, S. Understanding Dopaminergic Cell Death Pathways in Parkinson Disease. Neuron 2016, 90, 675–691. [Google Scholar] [CrossRef] [Green Version]
- Surmeier, D.J.; Schumacker, P.T.; Guzman, J.D.; Ilijic, E.; Yang, B.; Zampese, E. Calcium and Parkinson’s disease. Biochem. Biophys. Res. Commun. 2017, 483, 1013–1019. [Google Scholar] [CrossRef] [Green Version]
- Catterall, W.A. Voltage-gated calcium channels. Cold Spring Harb. Perspect. Biol. 2011, 3, a003947. [Google Scholar] [CrossRef] [PubMed]
- Brini, M.; Cali, T.; Ottolini, D.; Carafoli, E. Neuronal calcium signaling: Function and dysfunction. Cell. Mol. Life Sci. 2014, 71, 2787–2814. [Google Scholar] [CrossRef] [PubMed]
- Berridge, M.J. Neuronal calcium signaling. Neuron 1998, 21, P13–P26. [Google Scholar] [CrossRef] [Green Version]
- Schwaller, B. Cytosolic Ca2+ buffers. Cold Spring Harb. Perspect. Biol. 2010, 2, a004051. [Google Scholar] [CrossRef] [PubMed]
- Zampese, E.; Pizzo, P. Intracellular organelles in the saga of Ca2+ homeostasis: Different molecules for different purposes? Cell. Mol. Life Sci. 2012, 69, 1077–1104. [Google Scholar] [CrossRef]
- Bagur, R.; Hajnóczky, G. Intracellular Ca2+ Sensing: Its Role in Calcium Homeostasis and Signaling. Mol. Cell 2017, 66, 780–788. [Google Scholar] [CrossRef] [Green Version]
- Brini, M.; Carafoli, E. The plasma membrane Ca2+ ATPase and the plasma membrane sodium calcium exchanger cooperate in the regulation of cell calcium. Cold Spring Harb. Perspect. Biol. 2011, 3. [Google Scholar] [CrossRef]
- Karagas, N.E.; Venkatachalam, K. Roles for the Endoplasmic Reticulum in Regulation of Neuronal Calcium Homeostasis. Cells 2019, 8, 1232. [Google Scholar] [CrossRef] [Green Version]
- Choi, Y.M.; Kim, S.H.; Chung, S.; Uhm, D.Y.; Park, M.K. Regional interaction of endoplasmic reticulum Ca2+ signals between soma and dendrites through rapid luminal Ca2+ diffusion. J. Neurosci. 2006, 26, 12127–12136. [Google Scholar] [CrossRef] [Green Version]
- Myoung Kyu, P.; Yu Mi, C.; Yun Kyung, K.; Petersen, O.H. The Endoplasmic Reticulum as an Integrator of Multiple Dendritic Events. Neuroscientist 2007, 14, 68–77. [Google Scholar] [CrossRef]
- Pizzo, P.; Pozzan, T. Mitochondria-endoplasmic reticulum choreography: Structure and signaling dynamics. Trends Cell Biol. 2007, 17, 511–517. [Google Scholar] [CrossRef] [PubMed]
- Nunnari, J.; Suomalainen, A. Mitochondria: In sickness and in health. Cell 2012, 148, 1145–1159. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Giorgi, C.; Marchi, S.; Pinton, P. The machineries, regulation and cellular functions of mitochondrial calcium. Nat. Rev. Mol. Cell Biol. 2018, 19, 713–730. [Google Scholar] [CrossRef] [PubMed]
- Elfawy, H.A.; Das, B. Crosstalk between mitochondrial dysfunction, oxidative stress, and age related neurodegenerative disease: Etiologies and therapeutic strategies. Life Sci. 2019, 218, 165–184. [Google Scholar] [CrossRef] [PubMed]
- Pizzo, P.; Drago, I.; Filadi, R.; Pozzan, T. Mitochondrial Ca2+ homeostasis: Mechanism, role, and tissue specificities. Pflug. Arch. 2012, 464, 3–17. [Google Scholar] [CrossRef] [PubMed]
- Rizzuto, R.; De Stefani, D.; Raffaello, A.; Mammucari, C. Mitochondria as sensors and regulators of calcium signalling. Nat. Rev. Mol. Cell Biol. 2012, 13, 566–578. [Google Scholar] [CrossRef]
- Baughman, J.M.; Perocchi, F.; Girgis, H.S.; Plovanich, M.; Belcher-Timme, C.A.; Sancak, Y.; Bao, X.R.; Strittmatter, L.; Goldberger, O.; Bogorad, R.L.; et al. Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. Nature 2011, 476, 341–345. [Google Scholar] [CrossRef] [Green Version]
- De Stefani, D.; Raffaello, A.; Teardo, E.; Szabo, I.; Rizzuto, R. A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter. Nature 2011, 476, 336–340. [Google Scholar] [CrossRef]
- Penna, E.; Espino, J.; De Stefani, D.; Rizzuto, R. The MCU complex in cell death. Cell Calcium 2018, 69, 73–80. [Google Scholar] [CrossRef]
- Kamer, K.J.; Mootha, V.K. The molecular era of the mitochondrial calcium uniporter. Nat. Rev. Mol. Cell Biol. 2015, 16, 545–553. [Google Scholar] [CrossRef]
- De Stefani, D.; Rizzuto, R.; Pozzan, T. Enjoy the Trip: Calcium in Mitochondria Back and Forth. Annu. Rev. Biochem. 2016, 85, 161–192. [Google Scholar] [CrossRef] [PubMed]
- Rizzuto, R.; Brini, M.; Murgia, M.; Pozzan, T. Microdomains with high Ca2+ close to IP3-sensitive channels that are sensed by neighboring mitochondria. Science 1993, 262, 744–747. [Google Scholar] [CrossRef] [PubMed]
- Rizzuto, R.; Pinton, P.; Carrington, W.; Fay, F.S.; Fogarty, K.E.; Lifshitz, L.M.; Tuft, R.A.; Pozzan, T. Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca2+ responses. Science 1998, 280, 1763–1766. [Google Scholar] [CrossRef] [PubMed]
- Csordas, G.; Renken, C.; Varnai, P.; Walter, L.; Weaver, D.; Buttle, K.F.; Balla, T.; Mannella, C.A.; Hajnoczky, G. Structural and functional features and significance of the physical linkage between ER and mitochondria. J. Cell Biol. 2006, 174, 915–921. [Google Scholar] [CrossRef] [Green Version]
- Csordas, G.; Varnai, P.; Golenar, T.; Roy, S.; Purkins, G.; Schneider, T.G.; Balla, T.; Hajnoczky, G. Imaging interorganelle contacts and local calcium dynamics at the ER-mitochondrial interface. Mol. Cell 2010, 39, 121–132. [Google Scholar] [CrossRef]
- Giacomello, M.; Drago, I.; Bortolozzi, M.; Scorzeto, M.; Gianelle, A.; Pizzo, P.; Pozzan, T. Ca2+ hot spots on the mitochondrial surface are generated by Ca2+ mobilization from stores, but not by activation of store-operated Ca2+ channels. Mol. Cell 2010, 38, 280–290. [Google Scholar] [CrossRef]
- Rizzuto, R.; Duchen, M.R.; Pozzan, T. Flirting in little space: The ER/mitochondria Ca2+ liaison. Sci. STKE Signal Transduct. Knowl. Environ. 2004, 2004, re1. [Google Scholar] [CrossRef]
- Hayashi, T.; Rizzuto, R.; Hajnoczky, G.; Su, T.-P. MAM: More than just a housekeeper. Trends Cell Biol. 2009, 19, 81–88. [Google Scholar] [CrossRef] [Green Version]
- Rowland, A.A.; Voeltz, G.K. Endoplasmic reticulum-mitochondria contacts: Function of the junction. Nat. Rev. Mol. Cell Biol. 2012, 13, 607–625. [Google Scholar] [CrossRef] [Green Version]
- Csordas, G.; Weaver, D.; Hajnoczky, G. Endoplasmic Reticulum-Mitochondrial Contactology: Structure and Signaling Functions. Trends Cell Biol. 2018, 28, 523–540. [Google Scholar] [CrossRef]
- Ashrafi, G.; de Juan-Sanz, J.; Farrell, R.J.; Ryan, T.A. Molecular Tuning of the Axonal Mitochondrial Ca2+ Uniporter Ensures Metabolic Flexibility of Neurotransmission. Neuron 2020, 105, 678–687.e5. [Google Scholar] [CrossRef] [PubMed]
- Boyman, L.; Williams, G.S.; Khananshvili, D.; Sekler, I.; Lederer, W.J. NCLX: The mitochondrial sodium calcium exchanger. J. Mol. Cell. Cardiol. 2013, 59, 205–213. [Google Scholar] [CrossRef] [Green Version]
- Palty, R.; Silverman, W.F.; Hershfinkel, M.; Caporale, T.; Sensi, S.L.; Parnis, J.; Nolte, C.; Fishman, D.; Shoshan-Barmatz, V.; Herrmann, S.; et al. NCLX is an essential component of mitochondrial Na+/Ca2+ exchange. Proc. Natl. Acad. Sci. USA 2010, 107, 436–441. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Young, K.W.; Bampton, E.T.; Pinon, L.; Bano, D.; Nicotera, P. Mitochondrial Ca2+ signalling in hippocampal neurons. Cell Calcium 2008, 43, 296–306. [Google Scholar] [CrossRef] [PubMed]
- Devine, M.J.; Kittler, J.T. Mitochondria at the neuronal presynapse in health and disease. Nat. Rev. Neurosci. 2018, 19, 63–80. [Google Scholar] [CrossRef] [PubMed]
- Friel, D.D. Mitochondria as regulators of stimulus-evoked calcium signals in neurons. Cell Calcium 2000, 28, 307–316. [Google Scholar] [CrossRef] [PubMed]
- Babcock, D.F.; Hille, B. Mitochondrial oversight of cellular Ca2+ signaling. Curr. Opin. Neurobiol. 1998, 8, 398–404. [Google Scholar] [CrossRef]
- Szalai, G.; Krishnamurthy, R.; Hajnóczky, G. Apoptosis driven by IP(3)-linked mitochondrial calcium signals. EMBO J. 1999, 18, 6349–6361. [Google Scholar] [CrossRef]
- Brenner, C.; Moulin, M. Physiological roles of the permeability transition pore. Circ. Res. 2012, 111, 1237–1247. [Google Scholar] [CrossRef] [Green Version]
- Nicholls, D.G.; Budd, S.L. Mitochondria and neuronal survival. Physiol. Rev. 2000, 80, 315–360. [Google Scholar] [CrossRef] [Green Version]
- Agarwal, A.; Wu, P.H.; Hughes, E.G.; Fukaya, M.; Tischfield, M.A.; Langseth, A.J.; Wirtz, D.; Bergles, D.E. Transient Opening of the Mitochondrial Permeability Transition Pore Induces Microdomain Calcium Transients in Astrocyte Processes. Neuron 2017, 93, 587–605.e7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Martínez-Reyes, I.; Chandel, N.S. Mitochondrial TCA cycle metabolites control physiology and disease. Nat. Commun. 2020, 11, 102. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Magistretti, P.J.; Allaman, I. A cellular perspective on brain energy metabolism and functional imaging. Neuron 2015, 86, 883–901. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Surmeier, D.J.; Guzman, J.N.; Sanchez, J.; Schumacker, P.T. Physiological phenotype and vulnerability in Parkinson’s disease. Cold Spring Harb. Perspect. Med. 2012, 2, a009290. [Google Scholar] [CrossRef] [Green Version]
- Brookes, P.S.; Yoon, Y.; Robotham, J.L.; Anders, M.W.; Sheu, S.S. Calcium, ATP, and ROS: A mitochondrial love-hate triangle. Am. J. Physiol. Cell Physiol. 2004, 287, C817–C833. [Google Scholar] [CrossRef] [PubMed]
- Kann, O.; Kovacs, R. Mitochondria and neuronal activity. Am. J. Physiol. Cell Physiol. 2007, 292, C641–C657. [Google Scholar] [CrossRef]
- Griffiths, E.J.; Rutter, G.A. Mitochondrial calcium as a key regulator of mitochondrial ATP production in mammalian cells. Biochim. Biophys. Acta 2009, 1787, 1324–1333. [Google Scholar] [CrossRef] [Green Version]
- Rossi, A.; Pizzo, P.; Filadi, R. Calcium, mitochondria and cell metabolism: A functional triangle in bioenergetics. Biochim. Biophys. Acta Mol. Cell Res. 2019, 1866, 1068–1078. [Google Scholar] [CrossRef]
- Gellerich, F.N.; Gizatullina, Z.; Gainutdinov, T.; Muth, K.; Seppet, E.; Orynbayeva, Z.; Vielhaber, S. The control of brain mitochondrial energization by cytosolic calcium: The mitochondrial gas pedal. IUBMB Life 2013, 65, 180–190. [Google Scholar] [CrossRef]
- Llorente-Folch, I.; Rueda, C.B.; Pardo, B.; Szabadkai, G.; Duchen, M.R.; Satrustegui, J. The regulation of neuronal mitochondrial metabolism by calcium. J. Physiol. 2015, 593, 3447–3462. [Google Scholar] [CrossRef] [Green Version]
- Szibor, M.; Gizatullina, Z.; Gainutdinov, T.; Endres, T.; Debska-Vielhaber, G.; Kunz, M.; Karavasili, N.; Hallmann, K.; Schreiber, F.; Bamberger, A.; et al. Cytosolic, but not matrix, calcium is essential for adjustment of mitochondrial pyruvate supply. J. Biol. Chem. 2020, 295, 4383–4397. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Denton, R.M. Regulation of mitochondrial dehydrogenases by calcium ions. Biochim. Biophys. Acta 2009, 1787, 1309–1316. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rangaraju, V.; Calloway, N.; Ryan, T.A. Activity-driven local ATP synthesis is required for synaptic function. Cell 2014, 156, 825–835. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Verstreken, P.; Ly, C.V.; Venken, K.J.; Koh, T.W.; Zhou, Y.; Bellen, H.J. Synaptic mitochondria are critical for mobilization of reserve pool vesicles at Drosophila neuromuscular junctions. Neuron 2005, 47, 365–378. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Harris, J.J.; Jolivet, R.; Attwell, D. Synaptic energy use and supply. Neuron 2012, 75, 762–777. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hall, C.N.; Klein-Flugge, M.C.; Howarth, C.; Attwell, D. Oxidative phosphorylation, not glycolysis, powers presynaptic and postsynaptic mechanisms underlying brain information processing. J. Neurosci. 2012, 32, 8940–8951. [Google Scholar] [CrossRef]
- Chouhan, A.K.; Ivannikov, M.V.; Lu, Z.; Sugimori, M.; Llinas, R.R.; Macleod, G.T. Cytosolic calcium coordinates mitochondrial energy metabolism with presynaptic activity. J. Neurosci. 2012, 32, 1233–1243. [Google Scholar] [CrossRef] [Green Version]
- Pathak, D.; Shields, L.Y.; Mendelsohn, B.A.; Haddad, D.; Lin, W.; Gerencser, A.A.; Kim, H.; Brand, M.D.; Edwards, R.H.; Nakamura, K. The role of mitochondrially derived ATP in synaptic vesicle recycling. J. Biol. Chem. 2015, 290, 22325–22336. [Google Scholar] [CrossRef] [Green Version]
- Sheng, Z.H. The Interplay of Axonal Energy Homeostasis and Mitochondrial Trafficking and Anchoring. Trends Cell Biol. 2017, 27, 403–416. [Google Scholar] [CrossRef]
- Nichols, M.; Elustondo, P.A.; Warford, J.; Thirumaran, A.; Pavlov, E.V.; Robertson, G.S. Global ablation of the mitochondrial calcium uniporter increases glycolysis in cortical neurons subjected to energetic stressors. J. Cereb. Blood Flow Metab. 2017, 37, 3027–3041. [Google Scholar] [CrossRef] [Green Version]
- Raza, C.; Anjum, R.; Shakeel, N.U.A. Parkinson’s disease: Mechanisms, translational models and management strategies. Life Sci. 2019, 226, 77–90. [Google Scholar] [CrossRef] [PubMed]
- Surmeier, D.J.; Obeso, J.A.; Halliday, G.M. Selective neuronal vulnerability in Parkinson disease. Nat. Rev. Neurosci. 2017, 18, 101–113. [Google Scholar] [CrossRef] [PubMed]
- Grace, A.A.; Onn, S.P. Morphology and electrophysiological properties of immunocytochemically identified rat dopamine neurons recorded in vitro. J. Neurosci. 1989, 9, 3463–3481. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sanghera, M.K.; Trulson, M.E.; German, D.C. Electrophysiological properties of mouse dopamine neurons: In vivo and in vitro studies. Neuroscience 1984, 12, 793–801. [Google Scholar] [CrossRef]
- Grace, A.A.; Bunney, B.S. Intracellular and extracellular electrophysiology of nigral dopaminergic neurons—1. Identification and characterization. Neuroscience 1983, 10, 301–315. [Google Scholar] [CrossRef]
- Hainsworth, A.H.; Röper, J.; Kapoor, R.; Ashcroft, F.M. Identification and electrophysiology of isolated pars-compacta neurons from guinea-pig substantia nigra. Neuroscience 1991, 43, 81–93. [Google Scholar] [CrossRef]
- Paladini, C.A.; Roeper, J. Generating bursts (and pauses) in the dopamine midbrain neurons. Neuroscience 2014, 282, 109–121. [Google Scholar] [CrossRef]
- Surmeier, D.J.; Graves, S.M.; Shen, W. Dopaminergic modulation of striatal networks in health and Parkinson’s disease. Curr. Opin. Neurobiol. 2014, 29, 109–117. [Google Scholar] [CrossRef] [Green Version]
- Gerfen, C.R.; Surmeier, D.J. Modulation of striatal projection systems by dopamine. Annu. Rev. Neurosci. 2011, 34, 441–466. [Google Scholar] [CrossRef] [Green Version]
- Howe, M.W.; Dombeck, D.A. Rapid signalling in distinct dopaminergic axons during locomotion and reward. Nature 2016, 535, 505–510. [Google Scholar] [CrossRef]
- Yee, A.G.; Forbes, B.; Cheung, P.Y.; Martini, A.; Burrell, M.H.; Freestone, P.S.; Lipski, J. Action potential and calcium dependence of tonic somatodendritic dopamine release in the Substantia Nigra pars compacta. J. Neurochem. 2019, 148, 462–479. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Geffen, L.B.; Jessell, T.M.; Cuello, A.C.; Iversen, L.L. Release of dopamine from dendrites in rat substantia nigra. Nature 1976, 260, 258–260. [Google Scholar] [CrossRef] [PubMed]
- Chen, B.T.; Rice, M.E. Novel Ca2+ dependence and time course of somatodendritic dopamine release: Substantia nigra versus striatum. J. Neurosci. 2001, 21, 7841–7847. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mallet, N.; Delgado, L.; Chazalon, M.; Miguelez, C.; Baufreton, J. Cellular and Synaptic Dysfunctions in Parkinson’s Disease: Stepping out of the Striatum. Cells 2019, 8, 1005. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Collier, T.J.; Kanaan, N.M.; Kordower, J.H. Aging and Parkinson’s disease: Different sides of the same coin? Mov. Disord. Off. J. Mov. Disord. Soc. 2017, 32, 983–990. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Surmeier, D.J.; Halliday, G.M.; Simuni, T. Calcium, mitochondrial dysfunction and slowing the progression of Parkinson’s disease. Exp. Neurol. 2017, 298, 202–209. [Google Scholar] [CrossRef]
- Ping, H.X.; Shepard, P.D. Apamin-sensitive Ca(2+)-activated K+ channels regulate pacemaker activity in nigral dopamine neurons. Neuroreport 1996, 7, 809–814. [Google Scholar] [CrossRef]
- Shepard, P.D.; Stump, D. Nifedipine blocks apamin-induced bursting activity in nigral dopamine-containing neurons. Brain Res. 1999, 817, 104–109. [Google Scholar] [CrossRef]
- Puopolo, M.; Raviola, E.; Bean, B.P. Roles of subthreshold calcium current and sodium current in spontaneous firing of mouse midbrain dopamine neurons. J. Neurosci. 2007, 27, 645–656. [Google Scholar] [CrossRef] [Green Version]
- Neuhoff, H.; Neu, A.; Liss, B.; Roeper, J. I(h) channels contribute to the different functional properties of identified dopaminergic subpopulations in the midbrain. J. Neurosci. 2002, 22, 1290–1302. [Google Scholar] [CrossRef] [Green Version]
- Iyer, R.; Ungless, M.A.; Faisal, A.A. Calcium-activated SK channels control firing regularity by modulating sodium channel availability in midbrain dopamine neurons. Sci. Rep. 2017, 7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shi, W.X. Electrophysiological characteristics of dopamine neurons: A 35-year update. J. Neural Transm. Suppl. 2009, 73, 103–119. [Google Scholar] [CrossRef]
- Yung, W.H.; Häusser, M.A.; Jack, J.J. Electrophysiology of dopaminergic and non-dopaminergic neurones of the guinea-pig substantia nigra pars compacta in vitro. J. Physiol. 1991, 436, 643–667. [Google Scholar] [CrossRef] [PubMed]
- Gantz, S.C.; Ford, C.P.; Morikawa, H.; Williams, J.T. The Evolving Understanding of Dopamine Neurons in the Substantia Nigra and Ventral Tegmental Area. Annu. Rev. Physiol. 2018, 80, 219–241. [Google Scholar] [CrossRef] [PubMed]
- Nedergaard, S.; Flatman, J.A.; Engberg, I. Nifedipine- and omega-conotoxin-sensitive Ca2+ conductances in guinea-pig substantia nigra pars compacta neurones. J. Physiol. 1993, 466, 727–747. [Google Scholar]
- Mercuri, N.B.; Bonci, A.; Calabresi, P.; Stratta, F.; Stefani, A.; Bernardi, G. Effects of dihydropyridine calcium antagonists on rat midbrain dopaminergic neurones. Br. J. Pharmacol. 1994, 113, 831–838. [Google Scholar] [CrossRef] [Green Version]
- Philippart, F.; Destreel, G.; Merino-Sepúlveda, P.; Henny, P.; Engel, D.; Seutin, V. Differential Somatic Ca2+ Channel Profile in Midbrain Dopaminergic Neurons. J. Neurosci. Off. J. Soc. Neurosci. 2016, 36, 7234–7245. [Google Scholar] [CrossRef] [Green Version]
- Ortner, N.J.; Bock, G.; Dougalis, A.; Kharitonova, M.; Duda, J.; Hess, S.; Tuluc, P.; Pomberger, T.; Stefanova, N.; Pitterl, F.; et al. Lower Affinity of Isradipine for L-Type Ca2+ Channels during Substantia Nigra Dopamine Neuron-Like Activity: Implications for Neuroprotection in Parkinson’s Disease. J. Neurosci. 2017, 37, 6761–6777. [Google Scholar] [CrossRef] [Green Version]
- Benkert, J.; Hess, S.; Roy, S.; Beccano-Kelly, D.; Wiederspohn, N.; Duda, J.; Simons, C.; Patil, K.; Gaifullina, A.; Mannal, N.; et al. Cav2.3 channels contribute to dopaminergic neuron loss in a model of Parkinson’s disease. Nat. Commun. 2019, 10. [Google Scholar] [CrossRef]
- Dufour, M.A.; Woodhouse, A.; Goaillard, J.-M. Somatodendritic ion channel expression in substantia nigra pars compacta dopaminergic neurons across postnatal development. J. Neurosci. Res. 2014, 92, 981–999. [Google Scholar] [CrossRef]
- Guzman, J.N.; Sanchez-Padilla, J.; Chan, C.S.; Surmeier, D.J. Robust pacemaking in substantia nigra dopaminergic neurons. J. Neurosci. 2009, 29, 11011–11019. [Google Scholar] [CrossRef] [PubMed]
- Chan, C.S.; Guzman, J.N.; Ilijic, E.; Mercer, J.N.; Rick, C.; Tkatch, T.; Meredith, G.E.; Surmeier, D.J. ‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease. Nature 2007, 447, 1081–1086. [Google Scholar] [CrossRef] [PubMed]
- Hage, T.A.; Khaliq, Z.M. Tonic firing rate controls dendritic Ca2+ signaling and synaptic gain in substantia nigra dopamine neurons. J. Neurosci. 2015, 35, 5823–5836. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Guzman, J.N.; Ilijic, E.; Yang, B.; Sanchez-Padilla, J.; Wokosin, D.; Galtieri, D.; Kondapalli, J.; Schumacker, P.T.; Surmeier, D.J. Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress. J. Clin. Investig. 2018, 128, 2266–2280. [Google Scholar] [CrossRef] [Green Version]
- Guzman, J.N.; Sanchez-Padilla, J.; Wokosin, D.; Kondapalli, J.; Ilijic, E.; Schumacker, P.T.; Surmeier, D.J. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 2010, 468, 696–700. [Google Scholar] [CrossRef] [Green Version]
- Dryanovski, D.I.; Guzman, J.N.; Xie, Z.; Galteri, D.J.; Volpicelli-Daley, L.A.; Lee, V.M.; Miller, R.J.; Schumacker, P.T.; Surmeier, D.J. Calcium entry and alpha-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons. J. Neurosci. 2013, 33, 10154–10164. [Google Scholar] [CrossRef] [Green Version]
- Wilson, C.J.; Callaway, J.C. Coupled oscillator model of the dopaminergic neuron of the substantia nigra. J. Neurophysiol. 2000, 83, 3084–3100. [Google Scholar] [CrossRef]
- Weiss, N.; Zamponi, G.W. T-type calcium channels: From molecule to therapeutic opportunities. Int. J. Biochem. Cell Biol. 2019, 108, 34–39. [Google Scholar] [CrossRef]
- Perez-Reyes, E. Molecular Physiology of Low-Voltage-Activated T-type Calcium Channels. Physiol. Rev. 2003, 83, 117–161. [Google Scholar] [CrossRef] [Green Version]
- Galtieri, D.J.; Estep, C.M.; Wokosin, D.L.; Traynelis, S.; Surmeier, D.J. Pedunculopontine glutamatergic neurons control spike patterning in substantia nigra dopaminergic neurons. Elife 2017, 6. [Google Scholar] [CrossRef]
- Evans, R.C.; Zhu, M.; Khaliq, Z.M. Dopamine Inhibition Differentially Controls Excitability of Substantia Nigra Dopamine Neuron Subpopulations through T-Type Calcium Channels. J. Neurosci. 2017, 37, 3704–3720. [Google Scholar] [CrossRef] [PubMed]
- Wolfart, J.; Roeper, J. Selective coupling of T-type calcium channels to SK potassium channels prevents intrinsic bursting in dopaminergic midbrain neurons. J. Neurosci. 2002, 22, 3403–3413. [Google Scholar] [CrossRef] [Green Version]
- Lipscombe, D.; Helton, T.D.; Xu, W. L-type calcium channels: The low down. J. Neurophysiol. 2004, 92, 2633–2641. [Google Scholar] [CrossRef] [PubMed]
- Calin-Jageman, I.; Lee, A. Ca(v)1 L-type Ca2+ channel signaling complexes in neurons. J. Neurochem. 2008, 105, 573–583. [Google Scholar] [CrossRef] [PubMed]
- Takada, M.; Kang, Y.; Imanishi, M. Immunohistochemical localization of voltage-gated calcium channels in substantia nigra dopamine neurons. Eur. J. Neurosci. 2001, 13, 757–762. [Google Scholar] [CrossRef]
- Koschak, A.; Reimer, D.; Huber, I.; Grabner, M.; Glossmann, H.; Engel, J.; Striessnig, J. alpha 1D (Cav1.3) subunits can form l-type Ca2+ channels activating at negative voltages. J. Biol. Chem. 2001, 276, 22100–22106. [Google Scholar] [CrossRef] [Green Version]
- Scholze, A.; Plant, T.D.; Dolphin, A.C.; Nürnberg, B. Functional expression and characterization of a voltage-gated CaV1.3 (alpha1D) calcium channel subunit from an insulin-secreting cell line. Mol. Endocrinol. 2001, 15, 1211–1221. [Google Scholar] [CrossRef] [Green Version]
- Putzier, I.; Kullmann, P.H.; Horn, J.P.; Levitan, E.S. Cav1.3 channel voltage dependence, not Ca2+ selectivity, drives pacemaker activity and amplifies bursts in nigral dopamine neurons. J. Neurosci. 2009, 29, 15414–15419. [Google Scholar] [CrossRef]
- Fujimura, K.; Matsuda, Y. Autogenous oscillatory potentials in neurons of the guinea pig substantia nigra pars compacta in vitro. Neurosci. Lett. 1989, 104, 53–57. [Google Scholar] [CrossRef]
- Kang, Y.; Kitai, S.T. Calcium spike underlying rhytmic firing in dopaminergic neurons of the rat substantia nigra. Neurosci. Res. 1993, 18, 195–207. [Google Scholar] [CrossRef]
- Dragicevic, E.; Poetschke, C.; Duda, J.; Schlaudraff, F.; Lammel, S.; Schiemann, J.; Fauler, M.; Hetzel, A.; Watanabe, M.; Lujan, R.; et al. Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons. Brain J. Neurol. 2014, 137, 2287–2302. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Khaliq, Z.M.; Bean, B.P. Pacemaking in Dopaminergic Ventral Tegmental Area Neurons: Depolarizing Drive from Background and Voltage-Dependent Sodium Conductances. J. Neurosci. 2010, 30, 7401–7413. [Google Scholar] [CrossRef] [PubMed]
- Foehring, R.C.; Zhang, X.F.; Lee, J.C.; Callaway, J.C. Endogenous calcium buffering capacity of substantia nigral dopamine neurons. J. Neurophysiol. 2009, 102, 2326–2333. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shepard, P.D.; Bunney, B.S. Repetitive firing properties of putative dopamine-containing neurons in vitro: Regulation by an apamin-sensitive Ca2+-activated K+ conductance. Exp. Brain Res. 1991, 86, 141–150. [Google Scholar] [CrossRef]
- de Vrind, V.; Scuvee-Moreau, J.; Drion, G.; Hmaied, C.; Philippart, F.; Engel, D.; Seutin, V. Interactions between calcium channels and SK channels in midbrain dopamine neurons and their impact on pacemaker regularity: Contrasting roles of N- and L-type channels. Eur. J. Pharmacol. 2016, 788, 274–279. [Google Scholar] [CrossRef]
- Verkhratsky, A.; Shmigol, A. Calcium-induced calcium release in neurones. Cell Calcium 1996, 19, 1–14. [Google Scholar] [CrossRef]
- Kim, S.; Yun, H.-M.; Baik, J.-H.; Chung, K.C.; Nah, S.-Y.; Rhim, H. Functional Interaction of Neuronal Cav1.3 L-type Calcium Channel with Ryanodine Receptor Type 2 in the Rat Hippocampus. J. Biol. Chem. 2007, 282, 32877–32889. [Google Scholar] [CrossRef] [Green Version]
- Sanchez-Padilla, J.; Guzman, J.N.; Ilijic, E.; Kondapalli, J.; Galtieri, D.J.; Yang, B.; Schieber, S.; Oertel, W.; Wokosin, D.; Schumacker, P.T.; et al. Mitochondrial oxidant stress in locus coeruleus is regulated by activity and nitric oxide synthase. Nat. Neurosci. 2014, 17, 832–840. [Google Scholar] [CrossRef] [Green Version]
- Aumann, T.; Horne, M. Activity-dependent regulation of the dopamine phenotype in substantia nigra neurons. J. Neurochem. 2012, 121, 497–515. [Google Scholar] [CrossRef]
- Aumann, T.D.; Egan, K.; Lim, J.; Boon, W.C.; Bye, C.R.; Chua, H.K.; Baban, N.; Parish, C.L.; Bobrovskaya, L.; Dickson, P.; et al. Neuronal activity regulates expression of tyrosine hydroxylase in adult mouse substantia nigra pars compacta neurons. J. Neurochem. 2011, 116, 646–658. [Google Scholar] [CrossRef]
- Menezes, A.; Zeman, R.; Sabban, E. Involvement of intracellular or extracellular calcium in activation of tyrosine hydroxylase gene expression in PC12 cells. J. Neurochem. 1996, 67, 2316–2324. [Google Scholar] [CrossRef] [PubMed]
- Bolam, J.P.; Pissadaki, E.K. Living on the edge with too many mouths to feed: Why dopamine neurons die. Mov. Disord. Off. J. Mov. Disord. Soc. 2012, 27, 1478–1483. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pissadaki, E.K.; Bolam, J.P. The energy cost of action potential propagation in dopamine neurons: Clues to susceptibility in Parkinson’s disease. Front. Comput. Neurosci. 2013, 7, 13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Diederich, N.J.; James Surmeier, D.; Uchihara, T.; Grillner, S.; Goetz, C.G. Parkinson’s disease: Is it a consequence of human brain evolution? Mov. Disord. Off. J. Mov. Disord. Soc. 2019, 34, 453–459. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Giguère, N.; Burke Nanni, S.; Trudeau, L.-E. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson’s Disease. Front. Neurol. 2018, 9. [Google Scholar] [CrossRef]
- De Vos, K.J.; Grierson, A.J.; Ackerley, S.; Miller, C.C. Role of axonal transport in neurodegenerative diseases. Annu. Rev. Neurosci. 2008, 31, 151–173. [Google Scholar] [CrossRef]
- Millecamps, S.; Julien, J.P. Axonal transport deficits and neurodegenerative diseases. Nat. Rev. Neurosci. 2013, 14, 161–176. [Google Scholar] [CrossRef]
- Gennerich, A.; Vale, R.D. Walking the walk: How kinesin and dynein coordinate their steps. Curr. Opin. Cell Biol. 2009, 21, 59–67. [Google Scholar] [CrossRef] [Green Version]
- Maday, S.; Twelvetrees, A.E.; Moughamian, A.J.; Holzbaur, E.L.F. Axonal transport: Cargo-specific mechanisms of motility and regulation. Neuron 2014, 84, 292–309. [Google Scholar] [CrossRef] [Green Version]
- Pease, S.E.; Segal, R.A. Preserve and protect: Maintaining axons within functional circuits. Trends Neurosci. 2014, 37, 572–582. [Google Scholar] [CrossRef] [Green Version]
- Surmeier, D.J.; Schumacker, P.T. Calcium, bioenergetics, and neuronal vulnerability in Parkinson’s disease. J. Biol. Chem. 2013, 288, 10736–10741. [Google Scholar] [CrossRef] [Green Version]
- Andén, N.E.; Hfuxe, K.; Hamberger, B.; Hökfelt, T. A quantitative study on the nigro-neostriatal dopamine neuron system in the rat. Acta Physiol. Scand. 1966, 67, 306–312. [Google Scholar] [CrossRef]
- Matsuda, W.; Furuta, T.; Nakamura, K.C.; Hioki, H.; Fujiyama, F.; Arai, R.; Kaneko, T. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J. Neurosci. 2009, 29, 444–453. [Google Scholar] [CrossRef] [Green Version]
- Arbuthnott, G.W.; Wickens, J. Space, time and dopamine. Trends Neurosci. 2007, 30, 62–69. [Google Scholar] [CrossRef]
- Gauthier, J.; Parent, M.; Lévesque, M.; Parent, A. The axonal arborization of single nigrostriatal neurons in rats. Brain Res. 1999, 834, 228–232. [Google Scholar] [CrossRef]
- Fallon, J.H. Collateralization of monoamine neurons: Mesotelencephalic dopamine projections to caudate, septum, and frontal cortex. J. Neurosci. 1981, 1, 1361–1368. [Google Scholar] [CrossRef]
- Loughlin, S.E.; Fallon, J.H. Substantia nigra and ventral tegmental area projections to cortex: Topography and collateralization. Neuroscience 1984, 11, 425–435. [Google Scholar] [CrossRef]
- Kawaguchi, Y.; Wilson, C.J.; Emson, P.C. Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. J. Neurosci. 1990, 10, 3421–3428. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wu, Y.; Richard, S.; Parent, A. The organization of the striatal output system: A single-cell juxtacellular labeling study in the rat. Neurosci. Res. 2000, 38, 49–62. [Google Scholar] [CrossRef]
- Garcia-Ruiz, P.J.; Espay, A.J. Parkinson Disease: An Evolutionary Perspective. Front. Neurol. 2017, 8, 157. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pacelli, C.; Giguere, N.; Bourque, M.J.; Levesque, M.; Slack, R.S.; Trudeau, L.E. Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine Neurons. Curr. Biol. 2015, 25, 2349–2360. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Giguere, N.; Delignat-Lavaud, B.; Herborg, F.; Voisin, A.; Li, Y.; Jacquemet, V.; Anand-Srivastava, M.; Gether, U.; Giros, B.; Trudeau, L.E. Increased vulnerability of nigral dopamine neurons after expansion of their axonal arborization size through D2 dopamine receptor conditional knockout. PLoS Genet. 2019, 15, e1008352. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Balaban, R.S. Regulation of oxidative phosphorylation in the mammalian cell. Am. J. Physiol. Cell Physiol. 1990, 258, C377–C389. [Google Scholar] [CrossRef] [PubMed]
- Chance, B.; Williams, G.R. Respiratory enzymes in oxidative phosphorylation. I. Kinetics of oxygen utilization. J. Biol. Chem. 1955, 217, 383–393. [Google Scholar] [PubMed]
- Chance, B.; Williams, G.R. Respiratory enzymes in oxidative phosphorylation. VI. The effects of adenosine diphosphate on azide-treated mitochondria. J. Biol. Chem. 1956, 221, 477–489. [Google Scholar]
- Lardy, H.A.; Wellman, H. Oxidative phosphorylations; rôle of inorganic phosphate and acceptor systems in control of metabolic rates. J. Biol. Chem. 1952, 195, 215–224. [Google Scholar]
- Röper, J.; Ashcroft, F.M. Metabolic inhibition and low internal ATP activate K-ATP channels in rat dopaminergic substantia nigra neurones. Pflug. Arch. 1995, 430, 44–54. [Google Scholar] [CrossRef]
- Marinelli, S.; Bernardi, G.; Giacomini, P.; Mercuri, N.B. Pharmacological identification of the K+ currents mediating the hypoglycemic hyperpolarization of rat midbrain dopaminergic neurones. Neuropharmacology 2000, 39, 1021–1028. [Google Scholar] [CrossRef]
- Viola, H.M.; Arthur, P.G.; Hool, L.C. Evidence for regulation of mitochondrial function by the L-type Ca2+ channel in ventricular myocytes. J. Mol. Cell. Cardiol. 2009, 46, 1016–1026. [Google Scholar] [CrossRef]
- Díaz-Vegas, A.R.; Cordova, A.; Valladares, D.; Llanos, P.; Hidalgo, C.; Gherardi, G.; De Stefani, D.; Mammucari, C.; Rizzuto, R.; Contreras-Ferrat, A.; et al. Mitochondrial Calcium Increase Induced by RyR1 and IP3R Channel Activation After Membrane Depolarization Regulates Skeletal Muscle Metabolism. Front. Physiol. 2018, 9, 791. [Google Scholar] [CrossRef] [Green Version]
- Liss, B.; Haeckel, O.; Wildmann, J.; Miki, T.; Seino, S.; Roeper, J. K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons. Nat. Neurosci. 2005, 8, 1742–1751. [Google Scholar] [CrossRef]
- Guatteo, E.; Marinelli, S.; Geracitano, R.; Tozzi, A.; Federici, M.; Bernardi, G.; Mercuri, N.B. Dopamine-containing neurons are silenced by energy deprivation: A defensive response or beginning of cell death? Neurotoxicology 2005, 26, 857–868. [Google Scholar] [CrossRef]
- Hotka, M.; Cagalinec, M.; Hilber, K.; Hool, L.; Boehm, S.; Kubista, H. L-type Ca2+ channel-mediated Ca2+ influx adjusts neuronal mitochondrial function to physiological and pathophysiological conditions. Sci. Signal. 2020, 13. [Google Scholar] [CrossRef]
- Graves, S.M.; Xie, Z.; Stout, K.A.; Zampese, E.; Burbulla, L.F.; Shih, J.C.; Kondapalli, J.; Patriarchi, T.; Tian, L.; Brichta, L.; et al. Dopamine metabolism by a monoamine oxidase mitochondrial shuttle activates the electron transport chain. Nat. Neurosci. 2020, 23, 15–20. [Google Scholar] [CrossRef]
- Bisaglia, M.; Filograna, R.; Beltramini, M.; Bubacco, L. Are dopamine derivatives implicated in the pathogenesis of Parkinson’s disease? Ageing Res. Rev. 2014, 13, 107–114. [Google Scholar] [CrossRef]
- Asanuma, M.; Miyazaki, I.; Diaz-Corrales, F.J.; Ogawa, N. Quinone formation as dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic Parkinson’s disease and neurotoxin-induced parkinsonism. Acta Med. Okayama 2004, 58, 221–233. [Google Scholar]
- Burke, W.J.; Li, S.W.; Williams, E.A.; Nonneman, R.; Zahm, D.S. 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: Implications for Parkinson’s disease pathogenesis. Brain Res. 2003, 989, 205–213. [Google Scholar] [CrossRef]
- Mosharov, E.V.; Larsen, K.E.; Kanter, E.; Phillips, K.A.; Wilson, K.; Schmitz, Y.; Krantz, D.E.; Kobayashi, K.; Edwards, R.H.; Sulzer, D. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 2009, 62, 218–229. [Google Scholar] [CrossRef] [Green Version]
- Post, M.R.; Lieberman, O.J.; Mosharov, E.V. Can Interactions Between alpha-Synuclein, Dopamine and Calcium Explain Selective Neurodegeneration in Parkinson’s Disease? Front. Neurosci. 2018, 12, 161. [Google Scholar] [CrossRef]
- Segura-Aguilar, J.; Paris, I.; Munoz, P.; Ferrari, E.; Zecca, L.; Zucca, F.A. Protective and toxic roles of dopamine in Parkinson’s disease. J. Neurochem. 2014, 129, 898–915. [Google Scholar] [CrossRef]
- Zahid, M.; Saeed, M.; Yang, L.; Beseler, C.; Rogan, E.; Cavalieri, E.L. Formation of dopamine quinone-DNA adducts and their potential role in the etiology of Parkinson’s disease. IUBMB Life 2011, 63, 1087–1093. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jain, M.K.; Bhat, R. Modulation of human alpha-synuclein aggregation by a combined effect of calcium and dopamine. Neurobiol. Dis. 2014, 63, 115–128. [Google Scholar] [CrossRef] [PubMed]
- Burke, W.J.; Kumar, V.B.; Pandey, N.; Panneton, W.M.; Gan, Q.; Franko, M.W.; O’Dell, M.; Li, S.W.; Pan, Y.; Chung, H.D.; et al. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 2008, 115, 193–203. [Google Scholar] [CrossRef] [PubMed]
- Conway, K.A.; Rochet, J.C.; Bieganski, R.M.; Lansbury, P.T.J. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001, 294, 1346–1349. [Google Scholar] [CrossRef]
- Burbulla, L.F.; Song, P.; Mazzulli, J.R.; Zampese, E.; Wong, Y.C.; Jeon, S.; Santos, D.P.; Blanz, J.; Obermaier, C.D.; Strojny, C.; et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease. Science 2017, 357, 1255–1261. [Google Scholar] [CrossRef] [Green Version]
- Hirsch, E.; Graybiel, A.M.; Agid, Y.A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 1988, 334, 345–348. [Google Scholar] [CrossRef]
- Liang, C.L.; Sinton, C.M.; German, D.C. Midbrain dopaminergic neurons in the mouse: Co-localization with Calbindin-D28K and calretinin. Neuroscience 1996, 75, 523–533. [Google Scholar] [CrossRef]
- Fu, Y.; Yuan, Y.; Halliday, G.; Rusznák, Z.; Watson, C.; Paxinos, G. A cytoarchitectonic and chemoarchitectonic analysis of the dopamine cell groups in the substantia nigra, ventral tegmental area, and retrorubral field in the mouse. Brain Struct. Funct. 2012, 217, 591–612. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Damier, P.; Hirsch, E.C.; Agid, Y.; Graybiel, A.M. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain J. Neurol. 1999, 122 Pt 8, 1421–1436. [Google Scholar] [CrossRef] [Green Version]
- Yamada, T.; McGeer, P.L.; Baimbridge, K.G.; McGeer, E.G. Relative sparing in Parkinson’s disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res. 1990, 526, 303–307. [Google Scholar] [CrossRef]
- Liang, C.L.; Sinton, C.M.; Sonsalla, P.K.; German, D.C. Midbrain dopaminergic neurons in the mouse that contain calbindin-D28k exhibit reduced vulnerability to MPTP-induced neurodegeneration. Neurodegeneration 1996, 5, 313–318. [Google Scholar] [CrossRef] [PubMed]
- Gaspar, P.; Ben Jelloun, N.; Febvret, A. Sparing of the dopaminergic neurons containing calbindin-D28k and of the dopaminergic mesocortical projections in weaver mutant mice. Neuroscience 1994, 61, 293–305. [Google Scholar] [CrossRef]
- Mouatt-Prigent, A.; Agid, Y.; Hirsch, E.C. Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson’s disease? Brain Res. 1994, 668, 62–70. [Google Scholar] [CrossRef]
- Tsuboi, K.; Kimber, T.A.; Shults, C.W. Calretinin-containing axons and neurons are resistant to an intrastriatal 6-hydroxydopamine lesion. Brain Res. 2000, 866, 55–64. [Google Scholar] [CrossRef]
- Damier, P.; Hirsch, E.C.; Agid, Y.; Graybiel, A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain J. Neurol. 1999, 122 Pt 8, 1437–1448. [Google Scholar] [CrossRef]
- German, D.C.; Manaye, K.F.; Sonsalla, P.K.; Brooks, B.A. Midbrain dopaminergic cell loss in Parkinson’s disease and MPTP-induced parkinsonism: Sparing of calbindin-D28k-containing cells. Ann. N. Y. Acad. Sci. 1992, 648, 42–62. [Google Scholar] [CrossRef]
- Nagarajan, A.; Ning, Y.; Reisner, K.; Buraei, Z.; Larsen, J.P.; Hobert, O.; Doitsidou, M. Progressive degeneration of dopaminergic neurons through TRP channel-induced cell death. J. Neurosci. 2014, 34, 5738–5746. [Google Scholar] [CrossRef]
- Spillantini, M.G.; Crowther, R.A.; Jakes, R.; Hasegawa, M.; Goedert, M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA 1998, 95, 6469–6473. [Google Scholar] [CrossRef] [Green Version]
- Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. Alpha-synuclein in Lewy bodies. Nature 1997, 388, 839–840. [Google Scholar] [CrossRef]
- Braak, H.; Del Tredici, K.; Rüb, U.; de Vos, R.A.; Jansen Steur, E.N.; Braak, E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 2003, 24, 197–211. [Google Scholar] [CrossRef]
- Park, S.M.; Jung, H.Y.; Kim, T.D.; Park, J.H.; Yang, C.H.; Kim, J. Distinct roles of the N-terminal-binding domain and the C-terminal-solubilizing domain of alpha-synuclein, a molecular chaperone. J. Biol. Chem. 2002, 277, 28512–28520. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nath, S.; Goodwin, J.; Engelborghs, Y.; Pountney, D.L. Raised calcium promotes alpha-synuclein aggregate formation. Mol. Cell. Neurosci. 2011, 46, 516–526. [Google Scholar] [CrossRef] [PubMed]
- Lowe, R.; Pountney, D.L.; Jensen, P.H.; Gai, W.P.; Voelcker, N.H. Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain. Protein Sci. 2004, 13, 3245–3252. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Follett, J.; Darlow, B.; Wong, M.B.; Goodwin, J.; Pountney, D.L. Potassium depolarization and raised calcium induces alpha-synuclein aggregates. Neurotox. Res. 2013, 23, 378–392. [Google Scholar] [CrossRef]
- Nielsen, M.S.; Vorum, H.; Lindersson, E.; Jensen, P.H. Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerization. J. Biol. Chem. 2001, 276, 22680–22684. [Google Scholar] [CrossRef] [Green Version]
- Han, J.Y.; Choi, T.S.; Kim, H.I. Molecular Role of Ca2+ and Hard Divalent Metal Cations on Accelerated Fibrillation and Interfibrillar Aggregation of alpha-Synuclein. Sci. Rep. 2018, 8, 1895. [Google Scholar] [CrossRef] [Green Version]
- Martinez, J.; Moeller, I.; Erdjument-Bromage, H.; Tempst, P.; Lauring, B. Parkinson’s disease-associated alpha-synuclein is a calmodulin substrate. J. Biol. Chem. 2003, 278, 17379–17387. [Google Scholar] [CrossRef] [Green Version]
- Tamamizu-Kato, S.; Kosaraju, M.G.; Kato, H.; Raussens, V.; Ruysschaert, J.M.; Narayanaswami, V. Calcium-triggered membrane interaction of the alpha-synuclein acidic tail. Biochemistry 2006, 45, 10947–10956. [Google Scholar] [CrossRef] [Green Version]
- Rcom-H’cheo-Gauthier, A.N.; Meedeniya, A.C.; Pountney, D.L. Calcipotriol inhibits alpha-synuclein aggregation in SH-SY5Y neuroblastoma cells by a Calbindin-D28k-dependent mechanism. J. Neurochem. 2017, 141, 263–274. [Google Scholar] [CrossRef] [Green Version]
- Liu, J.; Liu, M.C.; Wang, K.K. Calpain in the CNS: From synaptic function to neurotoxicity. Sci. Signal. 2008, 1, re1. [Google Scholar] [CrossRef]
- Togari, A.; Ichikawa, S.; Nagatsu, T. Activation of tyrosine hydroxylase by Ca2+-dependent neutral protease, calpain. Biochem. Biophys. Res. Commun. 1986, 134, 749–754. [Google Scholar] [CrossRef]
- Kiuchi, K.; Kiuchi, K.; Titani, K.; Fujita, K.; Suzuki, K.; Nagatsu, T. Limited proteolysis of tyrosine hydroxylase by Ca(2+)-activated neutral protease (calpain). Biochemistry 1991, 30, 10416–10419. [Google Scholar] [CrossRef] [PubMed]
- Mishizen-Eberz, A.J.; Guttmann, R.P.; Giasson, B.I.; Day, G.A., 3rd; Hodara, R.; Ischiropoulos, H.; Lee, V.M.; Trojanowski, J.Q.; Lynch, D.R. Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J. Neurochem. 2003, 86, 836–847. [Google Scholar] [CrossRef] [PubMed]
- Dufty, B.M.; Warner, L.R.; Hou, S.T.; Jiang, S.X.; Gomez-Isla, T.; Leenhouts, K.M.; Oxford, J.T.; Feany, M.B.; Masliah, E.; Rohn, T.T. Calpain-cleavage of alpha-synuclein: Connecting proteolytic processing to disease-linked aggregation. Am. J. Pathol. 2007, 170, 1725–1738. [Google Scholar] [CrossRef] [Green Version]
- Diepenbroek, M.; Casadei, N.; Esmer, H.; Saido, T.C.; Takano, J.; Kahle, P.J.; Nixon, R.A.; Rao, M.V.; Melki, R.; Pieri, L.; et al. Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]alphaSyn transgenic mice. Hum. Mol. Genet. 2014, 23, 3975–3989. [Google Scholar] [CrossRef]
- Crocker, S.J.; Smith, P.D.; Jackson-Lewis, V.; Lamba, W.R.; Hayley, S.P.; Grimm, E.; Callaghan, S.M.; Slack, R.S.; Melloni, E.; Przedborski, S.; et al. Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson’s disease. J. Neurosci. 2003, 23, 4081–4091. [Google Scholar] [CrossRef]
- Angelova, P.R.; Ludtmann, M.H.; Horrocks, M.H.; Negoda, A.; Cremades, N.; Klenerman, D.; Dobson, C.M.; Wood, N.W.; Pavlov, E.V.; Gandhi, S.; et al. Ca2+ is a key factor in alpha-synuclein-induced neurotoxicity. J. Cell Sci. 2016, 129, 1792–1801. [Google Scholar] [CrossRef] [Green Version]
- Hettiarachchi, N.T.; Parker, A.; Dallas, M.L.; Pennington, K.; Hung, C.C.; Pearson, H.A.; Boyle, J.P.; Robinson, P.; Peers, C. alpha-Synuclein modulation of Ca2+ signaling in human neuroblastoma (SH-SY5Y) cells. J. Neurochem. 2009, 111, 1192–1201. [Google Scholar] [CrossRef]
- Lieberman, O.J.; Choi, S.J.; Kanter, E.; Saverchenko, A.; Frier, M.D.; Fiore, G.M.; Wu, M.; Kondapalli, J.; Zampese, E.; Surmeier, D.J.; et al. alpha-Synuclein-Dependent Calcium Entry Underlies Differential Sensitivity of Cultured SN and VTA Dopaminergic Neurons to a Parkinsonian Neurotoxin. eNeuro 2017, 4. [Google Scholar] [CrossRef] [Green Version]
- Mironov, S.L. alpha-Synuclein forms non-selective cation channels and stimulates ATP-sensitive potassium channels in hippocampal neurons. J. Physiol. 2015, 593, 145–159. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Caraveo, G.; Auluck, P.K.; Whitesell, L.; Chung, C.Y.; Baru, V.; Mosharov, E.V.; Yan, X.; Ben-Johny, M.; Soste, M.; Picotti, P.; et al. Calcineurin determines toxic versus beneficial responses to α-synuclein. Proc. Natl. Acad. Sci. USA 2014, 111, E3544–E3552. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Betzer, C.; Lassen, L.B.; Olsen, A.; Kofoed, R.H.; Reimer, L.; Gregersen, E.; Zheng, J.; Cali, T.; Gai, W.P.; Chen, T.; et al. Alpha-synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation. EMBO Rep. 2018, 19. [Google Scholar] [CrossRef] [PubMed]
- Yamada, K.; Iwatsubo, T. Extracellular alpha-synuclein levels are regulated by neuronal activity. Mol. Neurodegener 2018, 13, 9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Emmanouilidou, E.; Melachroinou, K.; Roumeliotis, T.; Garbis, S.D.; Ntzouni, M.; Margaritis, L.H.; Stefanis, L.; Vekrellis, K. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci. 2010, 30, 6838–6851. [Google Scholar] [CrossRef] [Green Version]
- Cali, T.; Ottolini, D.; Negro, A.; Brini, M. alpha-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions. J. Biol. Chem. 2012, 287, 17914–17929. [Google Scholar] [CrossRef] [Green Version]
- Murphy, M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2009, 417, 1–13. [Google Scholar] [CrossRef] [Green Version]
- Nickel, A.; Kohlhaas, M.; Maack, C. Mitochondrial reactive oxygen species production and elimination. J. Mol. Cell. Cardiol. 2014, 73, 26–33. [Google Scholar] [CrossRef]
- Stefanatos, R.; Sanz, A. The role of mitochondrial ROS in the aging brain. FEBS Lett. 2018, 592, 743–758. [Google Scholar] [CrossRef] [Green Version]
- Scheibye-Knudsen, M.; Fang, E.F.; Croteau, D.L.; Wilson, D.M., 3rd; Bohr, V.A. Protecting the mitochondrial powerhouse. Trends Cell Biol. 2014. [Google Scholar] [CrossRef] [Green Version]
- Votyakova, T.V.; Reynolds, I.J. DeltaPsi(m)-Dependent and -independent production of reactive oxygen species by rat brain mitochondria. J. Neurochem. 2001, 79, 266–277. [Google Scholar] [CrossRef]
- Dolle, C.; Flones, I.; Nido, G.S.; Miletic, H.; Osuagwu, N.; Kristoffersen, S.; Lilleng, P.K.; Larsen, J.P.; Tysnes, O.B.; Haugarvoll, K.; et al. Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. Nat. Commun. 2016, 7, 13548. [Google Scholar] [CrossRef] [PubMed]
- Muller, S.K.; Bender, A.; Laub, C.; Hogen, T.; Schlaudraff, F.; Liss, B.; Klopstock, T.; Elstner, M. Lewy body pathology is associated with mitochondrial DNA damage in Parkinson’s disease. Neurobiol. Aging 2013, 34, 2231–2233. [Google Scholar] [CrossRef] [PubMed]
- Sanders, L.H.; McCoy, J.; Hu, X.; Mastroberardino, P.G.; Dickinson, B.C.; Chang, C.J.; Chu, C.T.; Van Houten, B.; Greenamyre, J.T. Mitochondrial DNA damage: Molecular marker of vulnerable nigral neurons in Parkinson’s disease. Neurobiol. Dis. 2014, 70, 214–223. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bender, A.; Krishnan, K.J.; Morris, C.M.; Taylor, G.A.; Reeve, A.K.; Perry, R.H.; Jaros, E.; Hersheson, J.S.; Betts, J.; Klopstock, T.; et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 2006, 38, 515–517. [Google Scholar] [CrossRef] [PubMed]
- Kraytsberg, Y.; Kudryavtseva, E.; McKee, A.C.; Geula, C.; Kowall, N.W.; Khrapko, K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat. Genet. 2006, 38, 518–520. [Google Scholar] [CrossRef] [PubMed]
- Elstner, M.; Müller, S.K.; Leidolt, L.; Laub, C.; Krieg, L.; Schlaudraff, F.; Liss, B.; Morris, C.; Turnbull, D.M.; Masliah, E.; et al. Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions. Mol. Brain 2011, 4, 1–10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Greaves, L.C.; Reeve, A.K.; Taylor, R.W.; Turnbull, D.M. Mitochondrial DNA and disease. J. Pathol. 2012, 226, 274–286. [Google Scholar] [CrossRef]
- Keeney, P.M.; Xie, J.; Capaldi, R.A.; Bennett, J.P., Jr. Parkinson’s disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci. 2006, 26, 5256–5264. [Google Scholar] [CrossRef]
- Mann, V.M.; Cooper, J.M.; Daniel, S.E.; Srai, K.; Jenner, P.; Marsden, C.D.; Schapira, A.H. Complex I, iron, and ferritin in Parkinson’s disease substantia nigra. Ann. Neurol. 1994, 36, 876–881. [Google Scholar] [CrossRef]
- Schapira, A.H.; Cooper, J.M.; Dexter, D.; Clark, J.B.; Jenner, P.; Marsden, C.D. Mitochondrial complex I deficiency in Parkinson’s disease. J. Neurochem. 1990, 54, 823–827. [Google Scholar] [CrossRef]
- Schapira, A.H.; Mann, V.M.; Cooper, J.M.; Dexter, D.; Daniel, S.E.; Jenner, P.; Clark, J.B.; Marsden, C.D. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson’s disease. J. Neurochem. 1990, 55, 2142–2145. [Google Scholar] [CrossRef] [PubMed]
- Grunewald, A.; Rygiel, K.A.; Hepplewhite, P.D.; Morris, C.M.; Picard, M.; Turnbull, D.M. Mitochondrial DNA Depletion in Respiratory Chain-Deficient Parkinson Disease Neurons. Ann. Neurol. 2016, 79, 366–378. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liang, C.L.; Wang, T.T.; Luby-Phelps, K.; German, D.C. Mitochondria mass is low in mouse substantia nigra dopamine neurons: Implications for Parkinson’s disease. Exp. Neurol. 2007, 203, 370–380. [Google Scholar] [CrossRef] [PubMed]
- Ashrafi, G.; Schwarz, T.L. The pathways of mitophagy for quality control and clearance of mitochondria. Cell Death Differ. 2013, 20, 31–42. [Google Scholar] [CrossRef] [Green Version]
- McLelland, G.L.; Soubannier, V.; Chen, C.X.; McBride, H.M.; Fon, E.A. Parkin and PINK1 function in a vesicular trafficking pathway regulating mitochondrial quality control. EMBO J. 2014, 33, 282–295. [Google Scholar] [CrossRef]
- Hipp, M.S.; Kasturi, P.; Hartl, F.U. The proteostasis network and its decline in ageing. Nat. Rev. Mol. Cell Biol. 2019, 20, 421–435. [Google Scholar] [CrossRef]
- Haas, R.H.; Nasirian, F.; Nakano, K.; Ward, D.; Pay, M.; Hill, R.; Shults, C.W. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson’s disease. Ann. Neurol. 1995, 37, 714–722. [Google Scholar] [CrossRef]
- Ambrosi, G.; Ghezzi, C.; Sepe, S.; Milanese, C.; Payan-Gomez, C.; Bombardieri, C.R.; Armentero, M.T.; Zangaglia, R.; Pacchetti, C.; Mastroberardino, P.G.; et al. Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson’s disease. Biochim. Biophys. Acta 2014, 1842, 1385–1394. [Google Scholar] [CrossRef] [Green Version]
- Deus, C.M.; Pereira, S.P.; Cunha-Oliveira, T.; Pereira, F.B.; Raimundo, N.; Oliveira, P.J. Mitochondrial remodeling in human skin fibroblasts from sporadic PD male patients uncovers metabolic and mitochondrial bioenergetics defects. Biochim. Biophys. Acta Mol. Basis Dis. 2019, 165615. [Google Scholar] [CrossRef]
- Moon, H.E.; Yoon, S.H.; Hur, Y.S.; Park, H.W.; Ha, J.Y.; Kim, K.H.; Shim, J.H.; Yoo, S.H.; Son, J.H.; Paek, S.L.; et al. Mitochondrial dysfunction of immortalized human adipose tissue-derived mesenchymal stromal cells from patients with Parkinson’s disease. Exp. Neurobiol. 2013, 22, 283–300. [Google Scholar] [CrossRef] [Green Version]
- Muftuoglu, M.; Elibol, B.; Dalmizrak, O.; Ercan, A.; Kulaksiz, G.; Ogus, H.; Dalkara, T.; Ozer, N. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov. Disord. Off. J. Mov. Disord. Soc. 2004, 19, 544–548. [Google Scholar] [CrossRef] [PubMed]
- Smith, A.M.; Depp, C.; Ryan, B.J.; Johnston, G.I.; Alegre-Abarrategui, J.; Evetts, S.; Rolinski, M.; Baig, F.; Ruffmann, C.; Simon, A.K.; et al. Mitochondrial dysfunction and increased glycolysis in prodromal and early Parkinson’s blood cells. Mov. Disord. Off. J. Mov. Disord. Soc. 2018, 33, 1580–1590. [Google Scholar] [CrossRef] [PubMed]
- Mak, S.K.; Tewari, D.; Tetrud, J.W.; Langston, J.W.; Schule, B. Mitochondrial dysfunction in skin fibroblasts from a Parkinson’s disease patient with an alpha-synuclein triplication. J. Parkinsons Dis. 2011, 1, 175–183. [Google Scholar] [CrossRef] [PubMed]
- Mortiboys, H.; Thomas, K.J.; Koopman, W.J.; Klaffke, S.; Abou-Sleiman, P.; Olpin, S.; Wood, N.W.; Willems, P.H.; Smeitink, J.A.; Cookson, M.R.; et al. Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Ann. Neurol. 2008, 64, 555–565. [Google Scholar] [CrossRef] [PubMed]
- Teves, J.M.Y.; Bhargava, V.; Kirwan, K.R.; Corenblum, M.J.; Justiniano, R.; Wondrak, G.T.; Anandhan, A.; Flores, A.J.; Schipper, D.A.; Khalpey, Z.; et al. Parkinson’s Disease Skin Fibroblasts Display Signature Alterations in Growth, Redox Homeostasis, Mitochondrial Function, and Autophagy. Front. Neurosci. 2017, 11, 737. [Google Scholar] [CrossRef] [Green Version]
- Van der Merwe, C.; Loos, B.; Swart, C.; Kinnear, C.; Henning, F.; van der Merwe, L.; Pillay, K.; Muller, N.; Zaharie, D.; Engelbrecht, L.; et al. Mitochondrial impairment observed in fibroblasts from South African Parkinson’s disease patients with parkin mutations. Biochem. Biophys. Res. Commun. 2014, 447, 334–340. [Google Scholar] [CrossRef] [Green Version]
- Martinez, T.N.; Greenamyre, J.T. Toxin models of mitochondrial dysfunction in Parkinson’s disease. Antioxid. Redox Signal. 2012, 16, 920–934. [Google Scholar] [CrossRef] [Green Version]
- Tieu, K. A guide to neurotoxic animal models of Parkinson’s disease. Cold Spring Harb. Perspect. Med. 2011, 1, a009316. [Google Scholar] [CrossRef]
- Beal, M.F.; Oakes, D.; Shoulson, I.; Henchcliffe, C.; Galpern, W.R.; Haas, R.; Juncos, J.L.; Nutt, J.G.; Voss, T.S.; Ravina, B.; et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: No evidence of benefit. JAMA Neurol. 2014, 71, 543–552. [Google Scholar] [CrossRef]
- Kieburtz, K.; Tilley, B.C.; Elm, J.J.; Babcock, D.; Hauser, R.; Ross, G.W.; Augustine, A.H.; Augustine, E.U.; Aminoff, M.J.; Bodis-Wollner, I.G.; et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: A randomized clinical trial. JAMA 2015, 313, 584–593. [Google Scholar] [CrossRef]
- Snow, B.J.; Rolfe, F.L.; Lockhart, M.M.; Frampton, C.M.; O’Sullivan, J.D.; Fung, V.; Smith, R.A.; Murphy, M.P.; Taylor, K.M. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson’s disease. Mov. Disord. Off. J. Mov. Disord. Soc. 2010, 25, 1670–1674. [Google Scholar] [CrossRef] [PubMed]
- Choi, W.S.; Kruse, S.E.; Palmiter, R.D.; Xia, Z. Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat. Proc. Natl. Acad. Sci. USA 2008, 105, 15136–15141. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, H.W.; Choi, W.S.; Sorscher, N.; Park, H.J.; Tronche, F.; Palmiter, R.D.; Xia, Z. Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivo. Neurobiol. Aging 2015, 36, 2617–2627. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Choi, W.S.; Palmiter, R.D.; Xia, Z. Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson’s disease model. J. Cell Biol. 2011, 192, 873–882. [Google Scholar] [CrossRef]
- Choi, W.-S.; Kim, H.-W.; Tronche, F.; Palmiter, R.D.; Storm, D.R.; Xia, Z. Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson’s disease-like non-motor symptoms without loss of dopamine neurons. Sci. Rep. 2017, 7, 44989. [Google Scholar] [CrossRef]
- Inoue, N.; Ogura, S.; Kasai, A.; Nakazawa, T.; Ikeda, K.; Higashi, S.; Isotani, A.; Baba, K.; Mochizuki, H.; Fujimura, H.; et al. Knockdown of the mitochondria-localized protein p13 protects against experimental parkinsonism. EMBO Rep. 2018, 19. [Google Scholar] [CrossRef]
- Misgeld, T.; Schwarz, T.L. Mitostasis in Neurons: Maintaining Mitochondria in an Extended Cellular Architecture. Neuron 2017, 96, 651–666. [Google Scholar] [CrossRef] [Green Version]
- Chu, Y.; Morfini, G.A.; Langhamer, L.B.; He, Y.; Brady, S.T.; Kordower, J.H. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson’s disease. Brain J. Neurol. 2012, 135, 2058–2073. [Google Scholar] [CrossRef] [Green Version]
- Kim-Han, J.S.; Antenor-Dorsey, J.A.; O’Malley, K.L. The parkinsonian mimetic, MPP+, specifically impairs mitochondrial transport in dopamine axons. J. Neurosci. 2011, 31, 7212–7221. [Google Scholar] [CrossRef] [Green Version]
- Lu, X.; Kim-Han, J.S.; Harmon, S.; Sakiyama-Elbert, S.E.; O’Malley, K.L. The Parkinsonian mimetic, 6-OHDA, impairs axonal transport in dopaminergic axons. Mol. Neurodegener 2014, 9, 17. [Google Scholar] [CrossRef] [Green Version]
- Dukes, A.A.; Bai, Q.; Van Laar, V.S.; Zhou, Y.; Ilin, V.; David, C.N.; Agim, Z.S.; Bonkowsky, J.L.; Cannon, J.R.; Watkins, S.C.; et al. Live imaging of mitochondrial dynamics in CNS dopaminergic neurons in vivo demonstrates early reversal of mitochondrial transport following MPP(+) exposure. Neurobiol. Dis. 2016, 95, 238–249. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gottlieb, R.A.; Bernstein, D. Mitochondrial remodeling: Rearranging, recycling, and reprogramming. Cell Calcium 2016, 60, 88–101. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Friedman, J.R.; Nunnari, J. Mitochondrial form and function. Nature 2014, 505, 335–343. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Berthet, A.; Margolis, E.B.; Zhang, J.; Hsieh, I.; Zhang, J.; Hnasko, T.S.; Ahmad, J.; Edwards, R.H.; Sesaki, H.; Huang, E.J.; et al. Loss of mitochondrial fission depletes axonal mitochondria in midbrain dopamine neurons. J. Neurosci. 2014, 34, 14304–14317. [Google Scholar] [CrossRef] [Green Version]
- Pham, A.H.; Meng, S.; Chu, Q.N.; Chan, D.C. Loss of Mfn2 results in progressive, retrograde degeneration of dopaminergic neurons in the nigrostriatal circuit. Hum. Mol. Genet. 2012, 21, 4817–4826. [Google Scholar] [CrossRef]
- Lee, S.; Sterky, F.H.; Mourier, A.; Terzioglu, M.; Cullheim, S.; Olson, L.; Larsson, N.G. Mitofusin 2 is necessary for striatal axonal projections of midbrain dopamine neurons. Hum. Mol. Genet. 2012, 21, 4827–4835. [Google Scholar] [CrossRef] [Green Version]
- Ekstrand, M.I.; Terzioglu, M.; Galter, D.; Zhu, S.; Hofstetter, C.; Lindqvist, E.; Thams, S.; Bergstrand, A.; Hansson, F.S.; Trifunovic, A.; et al. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc. Natl. Acad. Sci. USA 2007, 104, 1325–1330. [Google Scholar] [CrossRef] [Green Version]
- Ekstrand, M.I.; Galter, D. The MitoPark Mouse—An animal model of Parkinson’s disease with impaired respiratory chain function in dopamine neurons. Parkinsonism Relat. Disord. 2009, 15, S185–S188. [Google Scholar] [CrossRef]
- Pickrell, A.M.; Pinto, M.; Hida, A.; Moraes, C.T. Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson’s disease. J. Neurosci. 2011, 31, 17649–17658. [Google Scholar] [CrossRef] [Green Version]
- Sterky, F.H.; Hoffman, A.F.; Milenkovic, D.; Bao, B.; Paganelli, A.; Edgar, D.; Wibom, R.; Lupica, C.R.; Olson, L.; Larsson, N.G. Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons. Hum. Mol. Genet. 2012, 21, 1078–1089. [Google Scholar] [CrossRef] [Green Version]
- Kruse, S.E.; Watt, W.C.; Marcinek, D.J.; Kapur, R.P.; Schenkman, K.A.; Palmiter, R.D. Mice with mitochondrial complex I deficiency develop a fatal encephalomyopathy. Cell Metab. 2008, 7, 312–320. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lin, M.K.; Farrer, M.J. Genetics and genomics of Parkinson’s disease. Genome Med. 2014, 6, 48. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Larsen, S.B.; Hanss, Z.; Krüger, R. The genetic architecture of mitochondrial dysfunction in Parkinson’s disease. Cell Tissue Res. 2018, 373, 21–37. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cieri, D.; Brini, M.; Calì, T. Emerging (and converging) pathways in Parkinson’s disease: Keeping mitochondrial wellness. Biochem. Biophys. Res. Commun. 2017, 483, 1020–1030. [Google Scholar] [CrossRef]
- Ludtmann, M.H.; Angelova, P.R.; Ninkina, N.N.; Gandhi, S.; Buchman, V.L.; Abramov, A.Y. Monomeric Alpha-Synuclein Exerts a Physiological Role on Brain ATP Synthase. J. Neurosci. 2016, 36, 10510–10521. [Google Scholar] [CrossRef]
- Ludtmann, M.H.R.; Angelova, P.R.; Horrocks, M.H.; Choi, M.L.; Rodrigues, M.; Baev, A.Y.; Berezhnov, A.V.; Yao, Z.; Little, D.; Banushi, B.; et al. alpha-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson’s disease. Nat. Commun. 2018, 9, 2293. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cali, T.; Ottolini, D.; Soriano, M.E.; Brini, M. A new split-GFP-based probe reveals DJ-1 translocation into the mitochondrial matrix to sustain ATP synthesis upon nutrient deprivation. Hum. Mol. Genet. 2015, 24, 1045–1060. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Heo, J.Y.; Park, J.H.; Kim, S.J.; Seo, K.S.; Han, J.S.; Lee, S.H.; Kim, J.M.; Park, J.I.; Park, S.K.; Lim, K.; et al. DJ-1 null dopaminergic neuronal cells exhibit defects in mitochondrial function and structure: Involvement of mitochondrial complex I assembly. PLoS ONE 2012, 7, e32629. [Google Scholar] [CrossRef] [PubMed]
- Morais, V.A.; Verstreken, P.; Roethig, A.; Smet, J.; Snellinx, A.; Vanbrabant, M.; Haddad, D.; Frezza, C.; Mandemakers, W.; Vogt-Weisenhorn, D.; et al. Parkinson’s disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function. EMBO Mol. Med. 2009, 1, 99–111. [Google Scholar] [CrossRef] [PubMed]
- Chen, R.; Park, H.A.; Mnatsakanyan, N.; Niu, Y.; Licznerski, P.; Wu, J.; Miranda, P.; Graham, M.; Tang, J.; Boon, A.J.W.; et al. Parkinson’s disease protein DJ-1 regulates ATP synthase protein components to increase neuronal process outgrowth. Cell Death Dis. 2019, 10, 469. [Google Scholar] [CrossRef] [Green Version]
- Lopez-Fabuel, I.; Martin-Martin, L.; Resch-Beusher, M.; Azkona, G.; Sanchez-Pernaute, R.; Bolanos, J.P. Mitochondrial respiratory chain disorganization in Parkinson’s disease-relevant PINK1 and DJ1 mutants. Neurochem. Int. 2017, 109, 101–105. [Google Scholar] [CrossRef] [PubMed]
- Zambon, F.; Cherubini, M.; Fernandes, H.J.R.; Lang, C.; Ryan, B.J.; Volpato, V.; Bengoa-Vergniory, N.; Vingill, S.; Attar, M.; Booth, H.D.E.; et al. Cellular alpha-synuclein pathology is associated with bioenergetic dysfunction in Parkinson’s iPSC-derived dopamine neurons. Hum. Mol. Genet. 2019, 28, 2001–2013. [Google Scholar] [CrossRef] [PubMed]
- Giguere, N.; Pacelli, C.; Saumure, C.; Bourque, M.J.; Matheoud, D.; Levesque, D.; Slack, R.S.; Park, D.S.; Trudeau, L.E. Comparative analysis of Parkinson’s disease-associated genes in mice reveals altered survival and bioenergetics of Parkin-deficient dopamine neurons. J. Biol. Chem. 2018, 293, 9580–9593. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, X.; Winter, D.; Ashrafi, G.; Schlehe, J.; Wong, Y.L.; Selkoe, D.; Rice, S.; Steen, J.; LaVoie, M.J.; Schwarz, T.L. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell 2011, 147, 893–906. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Saha, A.R.; Hill, J.; Utton, M.A.; Asuni, A.A.; Ackerley, S.; Grierson, A.J.; Miller, C.C.; Davies, A.M.; Buchman, V.L.; Anderton, B.H.; et al. Parkinson’s disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons. J. Cell Sci. 2004, 117, 1017–1024. [Google Scholar] [CrossRef] [Green Version]
- Liu, S.; Sawada, T.; Lee, S.; Yu, W.; Silverio, G.; Alapatt, P.; Millan, I.; Shen, A.; Saxton, W.; Kanao, T.; et al. Parkinson’s disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria. PLoS Genet. 2012, 8, e1002537. [Google Scholar] [CrossRef]
- Irrcher, I.; Aleyasin, H.; Seifert, E.L.; Hewitt, S.J.; Chhabra, S.; Phillips, M.; Lutz, A.K.; Rousseaux, M.W.; Bevilacqua, L.; Jahani-Asl, A.; et al. Loss of the Parkinson’s disease-linked gene DJ-1 perturbs mitochondrial dynamics. Hum. Mol. Genet. 2010, 19, 3734–3746. [Google Scholar] [CrossRef] [Green Version]
- Wang, X.; Petrie, T.G.; Liu, Y.; Liu, J.; Fujioka, H.; Zhu, X. Parkinson’s disease-associated DJ-1 mutations impair mitochondrial dynamics and cause mitochondrial dysfunction. J. Neurochem. 2012, 121, 830–839. [Google Scholar] [CrossRef]
- Pozo Devoto, V.M.; Dimopoulos, N.; Alloatti, M.; Pardi, M.B.; Saez, T.M.; Otero, M.G.; Cromberg, L.E.; Marín-Burgin, A.; Scassa, M.E.; Stokin, G.B.; et al. αSynuclein control of mitochondrial homeostasis in human-derived neurons is disrupted by mutations associated with Parkinson’s disease. Sci. Rep. 2017, 7, 5042. [Google Scholar] [CrossRef]
- Giaime, E.; Yamaguchi, H.; Gautier, C.A.; Kitada, T.; Shen, J. Loss of DJ-1 does not affect mitochondrial respiration but increases ROS production and mitochondrial permeability transition pore opening. PLoS ONE 2012, 7, e40501. [Google Scholar] [CrossRef] [Green Version]
- Zheng, L.; Bernard-Marissal, N.; Moullan, N.; D’Amico, D.; Auwerx, J.; Moore, D.J.; Knott, G.; Aebischer, P.; Schneider, B.L. Parkin functionally interacts with PGC-1α to preserve mitochondria and protect dopaminergic neurons. Hum. Mol. Genet. 2017, 26, 582–598. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shin, J.H.; Ko, H.S.; Kang, H.; Lee, Y.; Lee, Y.I.; Pletinkova, O.; Troconso, J.C.; Dawson, V.L.; Dawson, T.M. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson’s disease. Cell 2011, 144, 689–702. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pickrell, A.M.; Youle, R.J. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson’s disease. Neuron 2015, 85, 257–273. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Narendra, D.P.; Jin, S.M.; Tanaka, A.; Suen, D.F.; Gautier, C.A.; Shen, J.; Cookson, M.R.; Youle, R.J. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol. 2010, 8, e1000298. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nguyen, T.N.; Padman, B.S.; Lazarou, M. Deciphering the Molecular Signals of PINK1/Parkin Mitophagy. Trends Cell Biol. 2016, 26, 733–744. [Google Scholar] [CrossRef]
- Narendra, D.; Tanaka, A.; Suen, D.F.; Youle, R.J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 2008, 183, 795–803. [Google Scholar] [CrossRef] [Green Version]
- Heeman, B.; Van den Haute, C.; Aelvoet, S.A.; Valsecchi, F.; Rodenburg, R.J.; Reumers, V.; Debyser, Z.; Callewaert, G.; Koopman, W.J.; Willems, P.H.; et al. Depletion of PINK1 affects mitochondrial metabolism, calcium homeostasis and energy maintenance. J. Cell Sci. 2011, 124, 1115–1125. [Google Scholar] [CrossRef] [Green Version]
- Gandhi, S.; Wood-Kaczmar, A.; Yao, Z.; Plun-Favreau, H.; Deas, E.; Klupsch, K.; Downward, J.; Latchman, D.S.; Tabrizi, S.J.; Wood, N.W.; et al. PINK1-associated Parkinson’s disease is caused by neuronal vulnerability to calcium-induced cell death. Mol. Cell 2009, 33, 627–638. [Google Scholar] [CrossRef] [Green Version]
- Kostic, M.; Ludtmann, M.H.; Bading, H.; Hershfinkel, M.; Steer, E.; Chu, C.T.; Abramov, A.Y.; Sekler, I. PKA Phosphorylation of NCLX Reverses Mitochondrial Calcium Overload and Depolarization, Promoting Survival of PINK1-Deficient Dopaminergic Neurons. Cell Rep. 2015, 13, 376–386. [Google Scholar] [CrossRef] [Green Version]
- Huang, E.; Qu, D.; Huang, T.; Rizzi, N.; Boonying, W.; Krolak, D.; Ciana, P.; Woulfe, J.; Klein, C.; Slack, R.S.; et al. PINK1-mediated phosphorylation of LETM1 regulates mitochondrial calcium transport and protects neurons against mitochondrial stress. Nat. Commun. 2017, 8, 1399. [Google Scholar] [CrossRef]
- Matteucci, A.; Patron, M.; Vecellio Reane, D.; Gastaldello, S.; Amoroso, S.; Rizzuto, R.; Brini, M.; Raffaello, A.; Calì, T. Parkin-dependent regulation of the MCU complex component MICU1. Sci. Rep. 2018, 8. [Google Scholar] [CrossRef] [PubMed]
- Verma, M.; Callio, J.; Otero, P.A.; Sekler, I.; Wills, Z.P.; Chu, C.T. Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants. J. Neurosci. 2017, 37, 11151–11165. [Google Scholar] [CrossRef] [PubMed]
- Ludtmann, M.H.R.; Kostic, M.; Horne, A.; Gandhi, S.; Sekler, I.; Abramov, A.Y. LRRK2 deficiency induced mitochondrial Ca2+ efflux inhibition can be rescued by Na+/Ca2+/Li+ exchanger upregulation. Cell Death Dis. 2019, 10, 265. [Google Scholar] [CrossRef] [PubMed]
- Soman, S.K.; Bazała, M.; Keatinge, M.; Bandmann, O.; Kuznicki, J. Restriction of mitochondrial calcium overload by mcu inactivation renders a neuroprotective effect in zebrafish models of Parkinson’s disease. Biol. Open 2019, 8, bio044347. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Soman, S.; Keatinge, M.; Moein, M.; Da Costa, M.; Mortiboys, H.; Skupin, A.; Sugunan, S.; Bazala, M.; Kuznicki, J.; Bandmann, O. Inhibition of the mitochondrial calcium uniporter rescues dopaminergic neurons in pink1(-/-) zebrafish. Eur. J. Neurosci. 2017, 45, 528–535. [Google Scholar] [CrossRef]
- Ilijic, E.; Guzman, J.N.; Surmeier, D.J. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson’s disease. Neurobiol. Dis. 2011, 43, 364–371. [Google Scholar] [CrossRef] [Green Version]
- Kupsch, A.; Gerlach, M.; Pupeter, S.C.; Sautter, J.; Dirr, A.; Arnold, G.; Opitz, W.; Przuntek, H.; Riederer, P.; Oertel, W.H. Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport 1995, 6, 621–625. [Google Scholar] [CrossRef]
- Wang, Q.-M.; Xu, Y.-Y.; Liu, S.; Ma, Z.-G. Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice. Oncotarget 2017, 8, 47284–47295. [Google Scholar] [CrossRef] [Green Version]
- Wang, R.; Ma, Z.; Wang, J.; Xie, J. L-type Cav1.2 calcium channel is involved in 6-hydroxydopamine-induced neurotoxicity in rats. Neurotox. Res. 2012, 21, 266–270. [Google Scholar] [CrossRef]
- Singh, A.; Verma, P.; Balaji, G.; Samantaray, S.; Mohanakumar, K.P. Nimodipine, an L-type calcium channel blocker attenuates mitochondrial dysfunctions to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. Neurochem. Int. 2016, 99, 221–232. [Google Scholar] [CrossRef]
- Cali, T.; Ottolini, D.; Vicario, M.; Catoni, C.; Vallese, F.; Cieri, D.; Barazzuol, L.; Brini, M. splitGFP Technology Reveals Dose-Dependent ER-Mitochondria Interface Modulation by alpha-Synuclein A53T and A30P Mutants. Cells 2019, 8, 1072. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gautier, C.A.; Erpapazoglou, Z.; Mouton-Liger, F.; Muriel, M.P.; Cormier, F.; Bigou, S.; Duffaure, S.; Girard, M.; Foret, B.; Iannielli, A.; et al. The endoplasmic reticulum-mitochondria interface is perturbed in PARK2 knockout mice and patients with PARK2 mutations. Hum. Mol. Genet. 2016, 25, 2972–2984. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, K.S.; Huh, S.; Lee, S.; Wu, Z.; Kim, A.K.; Kang, H.Y.; Lu, B. Altered ER-mitochondria contact impacts mitochondria calcium homeostasis and contributes to neurodegeneration in vivo in disease models. Proc. Natl. Acad. Sci. USA 2018, 115, E8844–E8853. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ottolini, D.; Calì, T.; Negro, A.; Brini, M. The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum-mitochondria tethering. Hum. Mol. Genet. 2013, 22, 2152–2168. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.; Ma, X.; Fujioka, H.; Liu, J.; Chen, S.; Zhu, X. DJ-1 regulates the integrity and function of ER-mitochondria association through interaction with IP3R3-Grp75-VDAC1. Proc. Natl. Acad. Sci. USA 2019, 116, 25322–25328. [Google Scholar] [CrossRef] [PubMed]
- Guardia-Laguarta, C.; Area-Gomez, E.; Rub, C.; Liu, Y.; Magrane, J.; Becker, D.; Voos, W.; Schon, E.A.; Przedborski, S. alpha-Synuclein is localized to mitochondria-associated ER membranes. J. Neurosci. 2014, 34, 249–259. [Google Scholar] [CrossRef]
- Paillusson, S.; Gomez-Suaga, P.; Stoica, R.; Little, D.; Gissen, P.; Devine, M.J.; Noble, W.; Hanger, D.P.; Miller, C.C.J. alpha-Synuclein binds to the ER-mitochondria tethering protein VAPB to disrupt Ca2+ homeostasis and mitochondrial ATP production. Acta Neuropathol. 2017, 134, 129–149. [Google Scholar] [CrossRef] [Green Version]
- Gomez-Suaga, P.; Bravo-San Pedro, J.M.; Gonzalez-Polo, R.A.; Fuentes, J.M.; Niso-Santano, M. ER-mitochondria signaling in Parkinson’s disease. Cell Death Dis. 2018, 9, 337. [Google Scholar] [CrossRef] [Green Version]
- Parrado-Fernández, C.; Schneider, B.; Ankarcrona, M.; Conti, M.M.; Cookson, M.R.; Kivipelto, M.; Cedazo-Mínguez, Á.; Sandebring-Matton, A. Reduction of PINK1 or DJ-1 impair mitochondrial motility in neurites and alter ER-mitochondria contacts. J. Cell. Mol. Med. 2018, 22, 5439–5449. [Google Scholar] [CrossRef]
- Janikiewicz, J.; Szymanski, J.; Malinska, D.; Patalas-Krawczyk, P.; Michalska, B.; Duszynski, J.; Giorgi, C.; Bonora, M.; Dobrzyn, A.; Wieckowski, M.R. Mitochondria-associated membranes in aging and senescence: Structure, function, and dynamics. Cell Death Dis. 2018, 9, 332. [Google Scholar] [CrossRef]
- Erpapazoglou, Z.; Mouton-Liger, F.; Corti, O. From dysfunctional endoplasmic reticulum-mitochondria coupling to neurodegeneration. Neurochem. Int. 2017, 109, 171–183. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Paillusson, S.; Stoica, R.; Gomez-Suaga, P.; Lau, D.H.W.; Mueller, S.; Miller, T.; Miller, C.C.J. There’s Something Wrong with my MAM; the ER-Mitochondria Axis and Neurodegenerative Diseases. Trends Neurosci. 2016, 39, 146–157. [Google Scholar] [CrossRef] [Green Version]
- Sironi, L.; Restelli, L.M.; Tolnay, M.; Neutzner, A.; Frank, S. Dysregulated Interorganellar Crosstalk of Mitochondria in the Pathogenesis of Parkinson’s Disease. Cells 2020, 9, 233. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Celardo, I.; Costa, A.C.; Lehmann, S.; Jones, C.; Wood, N.; Mencacci, N.E.; Mallucci, G.R.; Loh, S.H.; Martins, L.M. Mitofusin-mediated ER stress triggers neurodegeneration in pink1/parkin models of Parkinson’s disease. Cell Death Dis. 2016, 7, e2271. [Google Scholar] [CrossRef] [Green Version]
- Toyofuku, T.; Okamoto, Y.; Ishikawa, T.; Sasawatari, S.; Kumanogoh, A. LRRK2 regulates endoplasmic reticulum-mitochondrial tethering through the PERK-mediated ubiquitination pathway. Embo J. 2020, 39, e100875. [Google Scholar] [CrossRef] [PubMed]
- Bezard, E.; Przedborski, S. A tale on animal models of Parkinson’s disease. Mov. Disord. Off. J. Mov. Disord. Soc. 2011, 26, 993–1002. [Google Scholar] [CrossRef]
- Dawson, T.M.; Ko, H.S.; Dawson, V.L. Genetic animal models of Parkinson’s disease. Neuron 2010, 66, 646–661. [Google Scholar] [CrossRef] [Green Version]
- Chia, S.J.; Tan, E.K.; Chao, Y.X. Historical Perspective: Models of Parkinson’s Disease. Int. J. Mol. Sci. 2020, 21, 2464. [Google Scholar] [CrossRef] [Green Version]
- Braak, H.; Del Tredici, K.; Bratzke, H.; Hamm-Clement, J.; Sandmann-Keil, D.; Rub, U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages). J. Neurol. 2002, 249 (Suppl. S3), iii1–iii5. [Google Scholar] [CrossRef]
- Braak, H.; Ghebremedhin, E.; Rub, U.; Bratzke, H.; Del Tredici, K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 2004, 318, 121–134. [Google Scholar] [CrossRef]
- Surmeier, D.J.; Obeso, J.A.; Halliday, G.M. Parkinson’s Disease Is Not Simply a Prion Disorder. J. Neurosci. 2017, 37, 9799–9807. [Google Scholar] [CrossRef] [Green Version]
- Greene, J.G. Causes and consequences of degeneration of the dorsal motor nucleus of the vagus nerve in Parkinson’s disease. Antioxid. Redox Signal. 2014, 21, 649–667. [Google Scholar] [CrossRef]
- Mo, Z.L.; Katafuchi, T.; Muratani, H.; Hori, T. Effects of vasopressin and angiotensin II on neurones in the rat dorsal motor nucleus of the vagus, in vitro. J. Physiol. 1992, 458, 561–577. [Google Scholar] [CrossRef]
- Travagli, R.A.; Gillis, R.A.; Rossiter, C.D.; Vicini, S. Glutamate and GABA-mediated synaptic currents in neurons of the rat dorsal motor nucleus of the vagus. Am. J. Physiol. 1991, 260, G531–G536. [Google Scholar] [CrossRef]
- Marks, J.D.; Donnelly, D.F.; Haddad, G.G. Adenosine-induced inhibition of vagal motoneuron excitability: Receptor subtype and mechanisms. Am. J. Physiol. 1993, 264, L124–L132. [Google Scholar] [CrossRef]
- Cooper, G.; Lasser-Katz, E.; Simchovitz, A.; Sharon, R.; Soreq, H.; Surmeier, D.J.; Goldberg, J.A. Functional segregation of voltage-activated calcium channels in motoneurons of the dorsal motor nucleus of the vagus. J. Neurophysiol. 2015, 114, 1513–1520. [Google Scholar] [CrossRef] [Green Version]
- Lasser-Katz, E.; Simchovitz, A.; Chiu, W.H.; Oertel, W.H.; Sharon, R.; Soreq, H.; Roeper, J.; Goldberg, J.A. Mutant alpha-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson’s Disease. J. Neurosci. 2017, 37, 47–57. [Google Scholar] [CrossRef] [Green Version]
- Goldberg, J.A.; Guzman, J.N.; Estep, C.M.; Ilijic, E.; Kondapalli, J.; Sanchez-Padilla, J.; Surmeier, D.J. Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson’s disease. Nat. Neurosci. 2012, 15, 1414–1421. [Google Scholar] [CrossRef]
- Pienaar, I.S.; Vernon, A.; Winn, P. The Cellular Diversity of the Pedunculopontine Nucleus: Relevance to Behavior in Health and Aspects of Parkinson’s Disease. Neuroscientist 2017, 23, 415–431. [Google Scholar] [CrossRef] [Green Version]
- Tubert, C.; Galtieri, D.; Surmeier, D.J. The pedunclopontine nucleus and Parkinson’s disease. Neurobiol. Dis. 2019, 128, 3–8. [Google Scholar] [CrossRef]
- Wang, H.L.; Morales, M. Pedunculopontine and laterodorsal tegmental nuclei contain distinct populations of cholinergic, glutamatergic and GABAergic neurons in the rat. Eur. J. Neurosci. 2009, 29, 340–358. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hirsch, E.C.; Graybiel, A.M.; Duyckaerts, C.; Javoy-Agid, F. Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc. Natl. Acad. Sci. USA 1987, 84, 5976–5980. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pienaar, I.S.; Elson, J.L.; Racca, C.; Nelson, G.; Turnbull, D.M.; Morris, C.M. Mitochondrial abnormality associates with type-specific neuronal loss and cell morphology changes in the pedunculopontine nucleus in Parkinson disease. Am. J. Pathol. 2013, 183, 1826–1840. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rinne, J.O.; Ma, S.Y.; Lee, M.S.; Collan, Y.; Roytta, M. Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson’s disease is related to disability of the patients. Parkinsonism Relat. Disord. 2008, 14, 553–557. [Google Scholar] [CrossRef] [PubMed]
- Dautan, D.; Hacioglu Bay, H.; Bolam, J.P.; Gerdjikov, T.V.; Mena-Segovia, J. Extrinsic Sources of Cholinergic Innervation of the Striatal Complex: A Whole-Brain Mapping Analysis. Front. Neuroanat 2016, 10, 1. [Google Scholar] [CrossRef] [Green Version]
- Dautan, D.; Huerta-Ocampo, I.; Witten, I.B.; Deisseroth, K.; Bolam, J.P.; Gerdjikov, T.; Mena-Segovia, J. A major external source of cholinergic innervation of the striatum and nucleus accumbens originates in the brainstem. J. Neurosci. 2014, 34, 4509–4518. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lavoie, B.; Parent, A. Pedunculopontine nucleus in the squirrel monkey: Projections to the basal ganglia as revealed by anterograde tract-tracing methods. J. Comp. Neurol. 1994, 344, 210–231. [Google Scholar] [CrossRef]
- Mena-Segovia, J.; Sims, H.M.; Magill, P.J.; Bolam, J.P. Cholinergic brainstem neurons modulate cortical gamma activity during slow oscillations. J. Physiol. 2008, 586, 2947–2960. [Google Scholar] [CrossRef]
- Ros, H.; Magill, P.J.; Moss, J.; Bolam, J.P.; Mena-Segovia, J. Distinct types of non-cholinergic pedunculopontine neurons are differentially modulated during global brain states. Neuroscience 2010, 170, 78–91. [Google Scholar] [CrossRef] [Green Version]
- Takakusaki, K.; Kitai, S.T. Ionic mechanisms involved in the spontaneous firing of tegmental pedunculopontine nucleus neurons of the rat. Neuroscience 1997, 78, 771–794. [Google Scholar] [CrossRef]
- Petzold, A.; Valencia, M.; Pal, B.; Mena-Segovia, J. Decoding brain state transitions in the pedunculopontine nucleus: Cooperative phasic and tonic mechanisms. Front. Neural Circuits 2015, 9, 68. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Scarnati, E.; Proia, A.; Di Loreto, S.; Pacitti, C. The reciprocal electrophysiological influence between the nucleus tegmenti pedunculopontinus and the substantia nigra in normal and decorticated rats. Brain Res. 1987, 423, 116–124. [Google Scholar] [CrossRef]
- Buchman, A.S.; Nag, S.; Shulman, J.M.; Lim, A.S.P.; VanderHorst, V.G.J.M.; Leurgans, S.E.; Schneider, J.A.; Bennett, D.A. Locus coeruleus neuron density and parkinsonism in older adults without Parkinson’s disease. Mov. Disord. 2012, 27, 1625–1631. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Del Tredici, K.; Rüb, U.; De Vos, R.A.; Bohl, J.R.; Braak, H. Where does parkinson disease pathology begin in the brain? J. Neuropathol. Exp. Neurol. 2002, 61, 413–426. [Google Scholar] [CrossRef]
- Alreja, M.; Aghajanian, G.K. Pacemaker activity of locus coeruleaus neurons: Whole-cell recordings in brain slices show dependence on cAMP and protein kinase A. Brain Res. 1991, 556, 339–343. [Google Scholar] [CrossRef]
- Graham, A.W.; Aghajanian, G.K. Effects of amphetamine on single cell activity in a catecholamine nucleus, the locus coeruleus. Nature 1971, 234, 100–102. [Google Scholar] [CrossRef]
- Masuko, S.; Nakajima, Y.; Nakajima, S.; Yamaguchi, K. Noradrenergic neurons from the locus ceruleus in dissociated cell culture: Culture methods, morphology, and electrophysiology. J. Neurosci. 1986, 6, 3229–3241. [Google Scholar] [CrossRef] [Green Version]
- Williams, J.T.; North, R.A.; Shefner, S.A.; Nishi, S.; Egan, T.M. Membrane properties of rat locus coeruleus neurones. Neuroscience 1984, 13, 137–156. [Google Scholar] [CrossRef]
- Aston-Jones, G.; Bloom, F.E. Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J. Neurosci. 1981, 1, 876–886. [Google Scholar] [CrossRef]
- Chu, N.; Bloom, F.E. Norepinephrine-containing neurons: Changes in spontaneous discharge patterns during sleeping and waking. Science 1973, 179, 908–910. [Google Scholar] [CrossRef]
- Foote, S.L.; Aston-Jones, G.; Bloom, F.E. Impulse activity of locus coeruleus neurons in awake rats and monkeys is a function of sensory stimulation and arousal. Proc. Natl. Acad. Sci. USA 1980, 77, 3033–3037. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gervasoni, D.; Darracq, L.; Fort, P.; Soulière, F.; Chouvet, G.; Luppi, P.-H. Electrophysiological evidence that noradrenergic neurons of the rat locus coeruleus are tonically inhibited by GABA during sleep. Eur. J. Neurosci. 1998, 10, 964–970. [Google Scholar] [CrossRef] [PubMed]
- Imber, A.N.; Putnam, R.W. Postnatal development and activation of L-type Ca2+ currents in locus ceruleus neurons: Implications for a role for Ca2+ in central chemosensitivity. J. Appl. Physiol. (1985) 2012, 112, 1715–1726. [Google Scholar] [CrossRef] [Green Version]
- Matschke, L.A.; Bertoune, M.; Roeper, J.; Snutch, T.P.; Oertel, W.H.; Rinne, S.; Decher, N. A concerted action of L- and T-type Ca2+ channels regulates locus coeruleus pacemaking. Mol. Cell. Neurosci. 2015, 68, 293–302. [Google Scholar] [CrossRef] [PubMed]
- Aston-Jones, G.; Waterhouse, B. Locus coeruleus: From global projection system to adaptive regulation of behavior. Brain Res. 2016, 1645, 75–78. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schwarz, L.A.; Luo, L. Organization of the locus coeruleus-norepinephrine system. Curr. Biol. 2015, 25, R1051–R1056. [Google Scholar] [CrossRef] [Green Version]
- Ungerstedt, U. Stereotaxic Mapping of the Monoamine Pathways in the Rat Brain. Acta Physiol. Scand. 1971, 82, 1–48. [Google Scholar] [CrossRef]
- Jones, B.E.; Moore, R.Y. Ascending projections of the locus coeruleus in the rat. II. Autoradiographic study. Brain Res. 1977, 127, 23–53. [Google Scholar] [CrossRef]
- Hornung, J.-P. The human raphe nuclei and the serotonergic system. J. Chem. Neuroanat. 2003, 26, 331–343. [Google Scholar] [CrossRef]
- Jacobs, B.L.; Azmitia, E.C. Structure and function of the brain serotonin system. Physiol. Rev. 1992, 72, 165–229. [Google Scholar] [CrossRef] [Green Version]
- Maeda, T.; Fujimiya, M.; Kitahama, K.; Imai, H.; Kimura, H. Serotonin neurons and their physiological roles. Arch. Histol. Cytol. 1989, 52, 113–120. [Google Scholar] [CrossRef] [Green Version]
- Michelsen, K.A.; Schmitz, C.; Steinbusch, H.W. The dorsal raphe nucleus—From silver stainings to a role in depression. Brain Res. Rev. 2007, 55, 329–342. [Google Scholar] [CrossRef]
- Muzerelle, A.; Scotto-Lomassese, S.; Bernard, J.F.; Soiza-Reilly, M.; Gaspar, P. Conditional anterograde tracing reveals distinct targeting of individual serotonin cell groups (B5-B9) to the forebrain and brainstem. Brain Struct. Funct. 2016, 221, 535–561. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vertes, R.P.; Linley, S.B. Comparison of projections of the dorsal and median raphe nuclei, with some functional considerations. Int. Congr. Ser. 2007, 1304, 98–120. [Google Scholar] [CrossRef]
- Crunelli, V.; Segal, M. An electrophysiological study of neurones in the rat median raphe and their projections to septum and hippocampus. Neuroscience 1985, 15, 47–60. [Google Scholar] [CrossRef]
- Heym, J.; Steinfels, G.F.; Jacobs, B.L. Activity of serotonin-containing neurons in the nucleus raphe pallidus of freely moving cats. Brain Res. 1982, 251, 259–276. [Google Scholar] [CrossRef]
- McGinty, D.J.; Harper, R.M. Dorsal raphe neurons: Depression of firing during sleep in cats. Brain Res. 1976, 101, 569–575. [Google Scholar] [CrossRef]
- Sakai, K. Sleep-waking discharge profiles of dorsal raphe nucleus neurons in mice. Neuroscience 2011, 197, 200–224. [Google Scholar] [CrossRef]
- Trulson, M.E.; Crisp, T.; Trulson, V.M. Activity of serotonin-containing nucleus centralis superior (Raphe medianus) neurons in freely moving cats. Exp. Brain Res. 1984, 54, 33–44. [Google Scholar] [CrossRef]
- Trulson, M.E.; Frederickson, C.J. A comparison of the electrophysiological and pharmacological properties of serotonin-containing neurons in the nucleus raphe dorsalis, raphe medianus and raphe pallidus recorded from mouse brain slices in vitro: Role of autoreceptors. Brain Res. Bull. 1987, 18, 179–190. [Google Scholar] [CrossRef]
- Trulson, M.E.; Jacobs, B.L. Raphe unit activity in freely moving cats: Correlation with level of behavioral arousal. Brain Res. 1979, 163, 135–150. [Google Scholar] [CrossRef]
- Urbain, N.; Creamer, K.; Debonnel, G. Electrophysiological diversity of the dorsal raphe cells across the sleep-wake cycle of the rat. J. Physiol. 2006, 573, 679–695. [Google Scholar] [CrossRef] [PubMed]
- Asaoka, N.; Nishitani, N.; Kinoshita, H.; Kawai, H.; Shibui, N.; Nagayasu, K.; Shirakawa, H.; Nakagawa, T.; Kaneko, S. Chronic antidepressant potentiates spontaneous activity of dorsal raphe serotonergic neurons by decreasing GABAB receptor-mediated inhibition of L-type calcium channels. Sci. Rep. 2017, 7, 13609. [Google Scholar] [CrossRef] [PubMed]
- Kirkwood, T.B.; Austad, S.N. Why do we age? Nature 2000, 408, 233–238. [Google Scholar] [CrossRef] [PubMed]
- Byars, S.G.; Voskarides, K. Antagonistic Pleiotropy in Human Disease. J. Mol. Evol. 2020, 88, 12–25. [Google Scholar] [CrossRef] [PubMed]
- Surmeier, D.J.; Guzman, J.N.; Sanchez-Padilla, J. Calcium, cellular aging, and selective neuronal vulnerability in Parkinson’s disease. Cell Calcium 2010, 47, 175–182. [Google Scholar] [CrossRef] [Green Version]
- Lees, A.J.; Hardy, J.; Revesz, T. Parkinson’s disease. Lancet 2009, 373, 2055–2066. [Google Scholar] [CrossRef]
- Dorsey, E.R.; Constantinescu, R.; Thompson, J.P.; Biglan, K.M.; Holloway, R.G.; Kieburtz, K.; Marshall, F.J.; Ravina, B.M.; Schifitto, G.; Siderowf, A.; et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68, 384–386. [Google Scholar] [CrossRef]
- Global, regional, and national burden of Parkinson’s disease, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018, 17, 939–953. [CrossRef] [Green Version]
- Rodriguez, M.; Rodriguez-Sabate, C.; Morales, I.; Sanchez, A.; Sabate, M. Parkinson’s disease as a result of aging. Aging Cell 2015, 14, 293–308. [Google Scholar] [CrossRef]
- Becker, C.; Jick, S.S.; Meier, C.R. Use of antihypertensives and the risk of Parkinson disease. Neurology 2008, 70, 1438–1444. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.C.; Lin, C.H.; Wu, R.M.; Lin, J.W.; Chang, C.H.; Lai, M.S. Antihypertensive agents and risk of Parkinson’s disease: A nationwide cohort study. PLoS ONE 2014, 9, e98961. [Google Scholar] [CrossRef] [PubMed]
- Marras, C.; Gruneir, A.; Rochon, P.; Wang, X.; Anderson, G.; Brotchie, J.; Bell, C.M.; Fox, S.; Austin, P.C. Dihydropyridine calcium channel blockers and the progression of parkinsonism. Ann. Neurol. 2012, 71, 362–369. [Google Scholar] [CrossRef] [PubMed]
- Pasternak, B.; Svanstrom, H.; Nielsen, N.M.; Fugger, L.; Melbye, M.; Hviid, A. Use of calcium channel blockers and Parkinson’s disease. Am. J. Epidemiol. 2012, 175, 627–635. [Google Scholar] [CrossRef] [PubMed]
- Ritz, B.; Rhodes, S.L.; Qian, L.; Schernhammer, E.; Olsen, J.H.; Friis, S. L-type calcium channel blockers and Parkinson disease in Denmark. Ann. Neurol. 2010, 67, 600–606. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kupsch, A.; Sautter, J.; Schwartz, J.; Rieder, P.; Gerlach, M.; Oertel, W.H. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res. 1996, 741, 185–196. [Google Scholar] [CrossRef]
- Liss, B.; Striessnig, J. The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson’s Disease. Annu. Rev. Pharmacol. Toxicol. 2019, 59, 263–289. [Google Scholar] [CrossRef]
- Parkinson Study Group STEADY-PD III Investigators. Isradipine Versus Placebo in Early Parkinson Disease. Ann. Internal Med. 2020, 172, 591–598. [Google Scholar] [CrossRef] [PubMed]
- Stern, M.B.; Lang, A.; Poewe, W. Toward a redefinition of Parkinson’s disease. Mov. Disord. Off. J. Mov. Disord. Soc. 2012, 27, 54–60. [Google Scholar] [CrossRef]
- Mantri, S.; Morley, J.F.; Siderowf, A.D. The importance of preclinical diagnostics in Parkinson disease. Parkinsonism Relat. Disord. 2019, 64, 20–28. [Google Scholar] [CrossRef]
- Tabata, Y.; Imaizumi, Y.; Sugawara, M.; Andoh-Noda, T.; Banno, S.; Chai, M.; Sone, T.; Yamazaki, K.; Ito, M.; Tsukahara, K.; et al. T-type Calcium Channels Determine the Vulnerability of Dopaminergic Neurons to Mitochondrial Stress in Familial Parkinson Disease. Stem Cell Rep. 2018, 11, 1171–1184. [Google Scholar] [CrossRef] [PubMed]
- Dey, K.; Bazala, M.A.; Kuznicki, J. Targeting mitochondrial calcium pathways as a potential treatment against Parkinson’s disease. Cell Calcium 2020, 89, 102216. [Google Scholar] [CrossRef] [PubMed]
- Tsunemi, T.; Perez-Rosello, T.; Ishiguro, Y.; Yoroisaka, A.; Jeon, S.; Hamada, K.; Rammonhan, M.; Wong, Y.C.; Xie, Z.; Akamatsu, W.; et al. Increased Lysosomal Exocytosis Induced by Lysosomal Ca2+ Channel Agonists Protects Human Dopaminergic Neurons from α-Synuclein Toxicity. J. Neurosci. 2019, 39, 5760–5772. [Google Scholar] [CrossRef] [PubMed] [Green Version]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zampese, E.; Surmeier, D.J. Calcium, Bioenergetics, and Parkinson’s Disease. Cells 2020, 9, 2045. https://doi.org/10.3390/cells9092045
Zampese E, Surmeier DJ. Calcium, Bioenergetics, and Parkinson’s Disease. Cells. 2020; 9(9):2045. https://doi.org/10.3390/cells9092045
Chicago/Turabian StyleZampese, Enrico, and D. James Surmeier. 2020. "Calcium, Bioenergetics, and Parkinson’s Disease" Cells 9, no. 9: 2045. https://doi.org/10.3390/cells9092045